

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 January 2004 (22.01.2004)

PCT

(10) International Publication Number
WO 2004/007505 A1

(51) International Patent Classification⁷: **C07D 501/00**,
A61K 31/546, A61P 31/04

[AT/AT]; Daxerfeld 3, A-6250 Kundl (AT). **HEIL-MAYER**, Werner [AT/AT]; Payergasse 4, A-2340 Mödling (AT). **SCHRANZ**, Michael [/]; Burghardtgasse 7/18, A-1200 Wien (AT). **WIESER**, Josef [AT/AT]; Siegfeld 92, A-6403 Polling (AT).

(21) International Application Number:
PCT/EP2003/007603

(22) International Filing Date: 14 July 2003 (14.07.2003)

(74) Agent: **GRUBB**, Philip; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0216418.4	15 July 2002 (15.07.2002)	GB
0222177.8	24 September 2002 (24.09.2002)	GB
0223976.2	15 October 2002 (15.10.2002)	GB
0223975.4	15 October 2002 (15.10.2002)	GB
0223974.7	15 October 2002 (15.10.2002)	GB
0223977.0	15 October 2002 (15.10.2002)	GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(71) Applicant (*for all designated States except US*): **SANDOZ GMBH** [AT/AT]; Biochemiestrasse 10, A-6250 Kundl (AT).

Published:



— with international search report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **ASCHER**, Gerd

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CEPHALOSPORINS




(57) Abstract: A compound of formula (IA) or of formula (IB), wherein the substituents have various meanings, useful as a pharmaceutical.


Cephalosporins

The present invention relates to cephalosporins.

5 In one aspect the present invention provides a compound of formula




or of formula



wherein

- 10 W is CH or N,
 R₁ is hydroxy, (C₁₋₆)alkoxy, halo(C₁₋₆)alkoxy, hydroxycarbonyl(C₁₋₆)alkoxy or (C₁₋₆)alkoxycarbonyl(C₁₋₆)alkoxy,
 R₂ is hydrogen or an ester moiety,
 R₃ is hydrogen, (C₁₋₆)alkyl, (C₂₋₆)alkenyl or (C₃₋₆)cycloalkyl,
 15 R₄ is hydrogen or (C₁₋₆)alkyl,



is cyclohexyl or phenyl,


- R₅ and R₆ independently of each other are hydrogen; (C₁₋₆)alkyl; (C₂₋₆)alkenyl; (C₆₋₁₈)arylcarbonyl; (C₁₋₆)alkylcarbonyl; (C₆₋₁₈)aryloxy(C₁₋₄)alkylcarbonyl; (C₁₋₆)alkylcarbonyl-(C₆₋₁₈)arylcarbonyl; heterocyclyl(C₁₋₆)alkylcarbonyl, wherein heterocyclyl comprises 5 or 6 ring
 20 members and 1 to 4 heteroatoms selected from N, O or S; (C₁₋₆)alkylsulfonyl or (C₆₋₁₈)arylsulfonyl,
 X is NH, O, S or N-R₈, wherein R₈ is (C₁₋₆)alkyl or (C₃₋₆)cycloalkyl,
 Y is O or S, and

- 2 -

n and m independently of each other are 0 or 1.

In a compound of formula IA or IB preferably

W, R₁, R₃, R₄, n, m and



5 are as defined above,

R₂ is hydrogen,

R₅ and R₆ independently of each other are hydrogen; (C₁₋₆)alkyl; (C₂₋₆)alkenyl;


(C₆₋₁₈)arylcarbonyl, wherein aryl is optionally substituted by (C₁₋₄)alkylcarbonyloxy;

(C₆₋₁₈)aryloxy(C₁₋₄)alkylcarbonyl; heterocyclyl(C₁₋₆)alkylcarbonyl, wherein heterocyclyl

10 comprises 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O or S;

(C₆₋₁₈)arylsulfonyl, wherein aryl is optionally substituted by amino or (C₁₋₄)alkylcarbonylamino;

X is NH, O, S or N-R₈, wherein R₈ is (C₁₋₆)alkyl or a group of formula



wherein R₉ and R₁₀ have the meaning of R₅ and R₆ as defined above, and

15 Y is S.

In a compound of formula IA or IB preferably n=0 and m= 0, or n=1 and m=1, or n=1 and m=0.

20 In a compound of formula IA or IB each single defined substituent may be a preferred substituent, e.g. independently of each other substituent defined.

In another aspect the present invention provides a compound of formula IA or IB wherein W is CH or N,


25 R₁ is hydroxy, methoxy, fluoromethoxy or (hydroxycarbonyl)(dimethyl)methoxy,

R₂ is hydrogen,

R₃ is hydrogen; (C₁₋₄)alkyl, e.g. methyl or ethyl; allyl or cyclopropyl,

R₄ is hydrogen or (C₁₋₄)alkyl, e.g. methyl,

- 3 -



is cyclohexyl, e.g. and the $-(CH_2)_m-NR_5R_6$ group is in the ortho, meta or para position,

R_5 and R_6 independently of each other are

- hydrogen;
 - 5 - (C_{1-3}) alkyl, e.g. methyl, ethyl, iso-propyl or n-propyl;
 - allyl;
 - (C_{1-4}) alkylcarbonyl, e.g. methylcarbonyl;
 - phenylcarbonyl, wherein phenyl is optionally substituted by (C_{1-4}) alkylcarbonyloxy, e.g. methylcarbonyloxy;
 - 10 - phenoxymethylcarbonyl;
 - phenylsulfonyl, wherein phenyl is substituted by amino or (C_{1-4}) alkylcarbonylamino, e.g. methylcarbonylamino; or
 - heterocyclyl comprising 5 ring members and 1 heteroatom selected from N, O or S, e.g. wherein heterocyclyl is aromatic heterocyclyl, e.g. thiophenyl, such as
 - 15 thiophenyl (C_{1-4}) alkylcarbonyl, e.g. thiophenylmethylcarbonyl;
- X is NH, NCH_3 , $NCH(CH_3)_2$, O, S or (C_{3-8}) cycloalkyl substituted by amino, such as cyclohexyl substituted by amino, e.g. in the para position,
- n is 0, m is 0,
- Y is S and
- 20 R_8 is (C_{1-4}) alkyl, e.g. methyl.


In another aspect the present invention provides a compound of formula IA wherein

W is N or CH,

R_1 is hydroxy or fluoromethoxy,

25 R_2 , R_4 , R_5 and R_6 are hydrogen,

R_3 is (C_{1-4}) alkyl, e.g. methyl,



is cyclohexyl, e.g. and the $-(CH_2)_m-NR_5R_6$ group is in the meta or para position,

X is NH,

n is 1 and m is 1.


In another aspect the present invention provides a compound of formula IA wherein

W is N,

R₁ is fluoromethoxy,

R₂, R₄, R₅ and R₆ are hydrogen,

5 R₃ is (C₁₋₄)alkyl, e.g. methyl,



is phenyl, e.g. and the $-(CH_2)_m-NR_5R_6$ group is in the meta position,

X is NH,

n is 1 and m is 0.


10 In another aspect the present invention provides a compound of formula IA wherein

W is CH or N,

R₁ is hydroxy or fluoromethoxy,

R₂, R₄, R₅ and R₆ are hydrogen,

R₃ is (C₁₋₄)alkyl, e.g. methyl,



15 is phenyl, e.g. and the $-(CH_2)_m-NR_5R_6$ group is in the meta or para position,

X is NH,

n is 1 and m is 1.

In another aspect the present invention provides a compound of formula IA wherein


20 W is N,

R₁ is fluoromethoxy,

R₂ is hydrogen or an ester moiety,

R₃ is (C₁₋₄)alkyl, e.g. methyl,

R₄, R₅ and R₆ are hydrogen,




25 is cyclohexyl, e.g. and the $-(CH_2)_m-NR_5R_6$ group is in the para position,

X is NH,

n is 0 and m is 0.

In another aspect the present invention provides a compound of formula



e.g. in the form of a hydrochloride.

- 5 An ester moiety as used herein includes alkyl; e.g. unsubstituted alkyl or substituted alkyl, e.g. by aryl, such as benzyl, alkoxybenzyl, such as 4-methoxybenzyl, alkoxy, such as methoxymethyl; alkyloxycarbonyloxy; alkyl; alkoxy, such as glycyloxy, phenylglycyloxy, e.g. glycyloxymethyl, phenylglycyloxymethyl; heterocyclyl e.g. 5-methyl-2-oxo-1,3-dioxolen-4-yl; indanyl, phthalidyl, alkoxy carbonyloxy and ester moieties which form with the COO⁻-group a
- 10 physiologically hydrolysable and acceptable ester, e.g. such as known to be hydrolysable ester groups in the field of cephalosporins. A compound of formula I may thus be in the form of an physiologically-hydrolysable and -acceptable ester. By physiologically-hydrolysable and -acceptable esters as used herein is meant an ester in which the COO⁻-group is esterified and which is hydrolysable under physiological conditions to yield an acid which is itself
- 15 physiologically tolerable at dosages to be administered. The term is thus to be understood as defining regular pro-drug forms. An ester moiety may be preferably a group which is easily hydrolysable under physiological conditions. Such esters may be administered preferably orally. Parenteral administration may be indicated if the ester *per se* is an active compound or, if hydrolysis occurs in the blood.
- 20 If not otherwise defined herein, aryl includes (C₆₋₁₈)aryl, e.g. phenyl. Any group(s) may be unsubstituted or one or morefold substituted, e.g. by groups as conventional in cephalosporin chemistry.


- 25 Compounds provided by the present invention are hereinafter designated as "compound(s) of (according to) the present invention". A compound of the present invention includes a compound in any form, e.g. in free form, in the form of a salt, in the form of a solvate and in the form of a salt and a solvate.

In another aspect the present invention provides a compound of the present invention in the form of a salt.

Such salts include preferably pharmaceutically acceptable salts, although pharmaceutically unacceptable salts are included, e.g. for preparation / isolation / purification purposes.

A salt of a compound of the present invention includes a metal salts, acid addition salts, amine salts, and inner salts and quaternary salts, where possible. Metal salts include for example alkali or earth alkali salts, preferably sodium or potassium salts; acid addition salts include salts of a compound of formula I with an acid, e.g. hydrogen fumaric acid, fumaric acid, naphthalin-1,5-sulphonic acid, hydrochloric acid, deuteriochloric acid; preferably hydrochloric acid.

Amine salts include for example trialkylamine, procaine, dibenzylamine and benzylamine salts, e.g. the amine group attached to the ring of formula




in a compound of formula IA or IB may be positively charged, e.g. in the form of a NH_3^+ , NH_2R_5^+ , NH_2R_6^+ or $\text{NR}_5\text{R}_6\text{R}_7^+$ group, wherein R_5 and R_6 are as defined above, with the exception of hydrogen, preferably R_5 and R_6 are (C_{1-4}) alkyl; and R_7 is (C_{1-4}) alkyl, e.g. methyl, more preferably R_5 , R_6 and R_7 are methyl; with a negatively charged counterion, e.g. selected from counterions as conventional, such as hydroxy, halogen, e.g. chloride. A compound of the present invention in the form of a salt includes a compound of the present invention in the form of


- a salt with an acid,
- a salt with an an amine,
- a metal salt,
- a salt with more than one acid, e.g. in the form of a hydrochloride and additionally in the form of an hydroiodide, and
- a salt with an acid and additionally in the form of an amine salt, e.g. a $\text{tri}(\text{C}_{1-4})$ alkylammonium salt, such as a trimethylammonium salt and additionally a hydrochloride,

preferably a salt with one or two acids, a salt with an amine, or a salt with an amine and additionally with an acid.

In another aspect the present invention provides a compound of the present invention in the form of a salt, which is a compound of formula I_{SALT}, including a compound of formula




or of formula



5

wherein



, W, R₁, R₂, R₃, R₄, R₅, R₆, R₈, X, Y, m and n are as defined above,


R₇ is (C₁₋₄)alkyl, e.g. methyl, and

- 10 AN⁻ is a negatively charged counterion, e.g. selected from counterions as conventional, such as hydroxy, halogenide, e.g. chloride.

Preferably a compound of formula I_{SALT} is a compound of IA_{SALT}.

In a compound of formula I_{SALT}, e.g. a compound of formula IA_{SALT}, **preferably**

- 15
- W is N,
 - R₁ is halo(C₁₋₆)alkoxy, e.g. -OCH₂F,
 - R₂ and R₄ are hydrogen,
 - R₃ is hydrogen or (C₁₋₄)alkyl, e.g. methyl,



- is cyclohexyl,

- 20
- R₅, R₆ and R₇ independently of each other are (C₁₋₄)alkyl, e.g. methyl,
 - X is NH or N-(C₁₋₄)alkyl,
 - n and m are 0, and


- AN⁻ is halogenide, e.g. chloride.

A compound of the present invention in free form may be converted into a corresponding compound in the form of a salt; and vice versa.

- 5 A compound of the present invention may exist in the form of isomers and mixtures thereof; e.g. optical isomers, diastereoisomers, cis/trans conformers, geometrical isomers. A compound of the present invention may e.g. contain asymmetric carbon atoms and may thus exist in the form of enantiomers or diastereoisomers and mixtures thereof, e.g. racemates. Any asymmetric carbon atom may be present in the (R)-, (S)- or (R,S)-configuration, preferably in the (R)- or (S)-configuration.

For example, the group R₁ attached to the imino group in a compound of formula I may be in the syn (Z) or anti (E) configuration and is preferably in the syn configuration.


E.g., if




- 15 is cyclohexyl, the groups -NR₄- and -(CH₂)_m-NR₅R₆- attached to it may be in cis or in trans configuration.

Isomeric mixtures may be separated as appropriate, e.g. according, e.g. analogously, to a method as conventional, to obtain pure isomers. The present invention includes a compound of the present invention in any isomeric form and in any isomeric mixture.

- 20 The present invention also includes tautomers of a compound of formula I, where tautomers can exist. E.g. the group




in a compound of formula IA, wherein R₃ and/or R₄ is/are hydrogen is in a chemical equilibrium with one of the following groups, depending on the meaning of R₃ and R₄:




- 25 The present invention includes a compound of the present invention in any tautomeric form.

Any compound mentioned herein, e.g. a compound of the present invention, may be prepared as appropriate, e.g. according, such as analogously, to a method as conventional or as disclosed herein.


- 5 In another aspect the present invention provides a process for the production of a compound of formula IA or IB comprising reacting a compound of formula




wherein R_1 , R_2 and W are as defined above, with a compound of formula



10 or



wherein



, X , Y , R_3 , R_4 , R_5 , R_6 , R_8 , n and m are as defined above, and isolating a compound of formula IA or IB obtained from the reaction mixture.

15

In an intermediate of formula III or of formula IVA or IVB (starting materials), functional groups, if present, optionally may be in protected form or in the form of a salt, if a salt-forming group is present. Protecting groups, optionally present, may be removed at an appropriate stage, e.g. according, e.g. analogously, to a method as conventional.

20

In another aspect the present invention provides an intermediate in the production of a compound of formula IA or IB, which intermediate is a compound of formula IVA or IVB as defined above.

- 5 Compounds of formula IVA or IVB are designated herein as "Intermediates of (according to) the present invention". The intermediates of the present invention, e.g. such as specified and obtained according to the Examples (Examples A to N), are useful in the production of compounds of formula IA and IB. Intermediates of formula IVA or IVB include intermediates in free base form, e.g. and in the form of a salt and/or optionally in the form of a solvent or in
10 the form of a salt and a solvent, preferably in the form of a salt.

- A compound of formula IA or IB thus obtained may be converted into another compound of formula IA or IB, respectively, e.g. a compound of formula IA or IB wherein R_2 is hydrogen may be converted into a compound of formula IA or IB wherein R_2 is an ester moiety, e.g. or
15 a compound of formula IA or IB obtained in free form may be converted into a salt of a compound of formula IA or IB and vice versa. A compound of formula IA or IB may be isolated from the reaction mixture as appropriate, e.g. analogously to a method as conventional.

- 20 The above reaction is a condensation reaction of N-containing nucleophiles to a carbonyl and may be carried out as appropriate, e.g. according, e.g. analogously to a method as conventional.

- Intermediates (starting materials) of formula III and of formula IVA or IVB are known or may
25 be prepared as appropriate, e.g. analogously, to a method as conventional or as specified.

- Any compound described herein, e.g. a compound of the present invention and intermediates of formulae III, IVA and IVB may be prepared as appropriate, e.g. according, e.g. analogously, to a method as conventional, e.g. or as specified herein.

- 30 The compounds of the present invention, e.g. including a compound of formula IA or IB, exhibit pharmacological activity, e.g. beside low toxicity, and are therefore useful as pharmaceuticals. E.g., the compounds of the present invention exhibit antimicrobial, e.g. antibacterial, activity against e.g. gram negative and gram positive, bacteria, e.g. gram

negative bacteria, such as *Escherichia*, e.g. *Escherichia coli*; *Enterobacter*, e.g. *Enterobacter cloacae* and *Enterobacter faecalis*; *Enterococcus*, e.g. *Enterococcus faecalis*; *Klebsiella*, e.g. *Klebsiella pneumoniae* and *Klebsiella edwardii*; *Streptococcus*, e.g. *Streptococcus pneumoniae* and *Streptococcus pyogenes*; and *Pseudomonas*, e.g. *Pseudomonas aeruginosa*, e.g. and gram positive bacteria, such as *Staphylococcus*, e.g. *Staphylococcus aureus*;

- in vitro in the Agar Dilution Test according to National Committee for Clinical Laboratory Standards (NCCLS) 1993, Document M7-A3 Vol.13, No. 25: "Methods for dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically -Third Edition, Approved Standard"; and Document M11-A3 for anaerobic bacteria,

in a concentration from about 0.001 to ca. 50 µg/ml (MIC) e.g. using strains including *Staphylococcus aureus* (ATCC 29213 and ATCC 9144); *Enterococcus faecalis* (ATCC 29212); *Haemophilus influenza* (NTCC 49247 and NCTC 11931); *Escherichia coli* (ATCC 25922 and ATCC 35218); *Klebsiella pneumoniae* (ATCC 11228); *Klebsiella edwardsii* (ATCC 10896); and

- in vivo in the septicaemia mouse model, in accordance to the method description Nr. 159 A-5, approved by Austrian Health Authorities (MA 58, no. 2968/95 of 12-Oct-1995), e.g. when administered at dosages from about 0.05 to 50 mg/kg body weight, such as ED₅₀ values of about 0.1 to 50 mg/kg body weight. E.g., in that model mice are infected with an ED 95% of *Staphylococcus aureus* (ATCC 4995), *Streptococcus pyogenes* (ATCC 29218), *Escherichia coli* and are treated 1 and 4 hours after infection. The ED₅₀ values after subcutaneous administration with a compound of the present invention are calculated by Probit analysis of the administered dosages of compounds. Activity is determined by numbers of surviving animals per group of 8 mice per dosage unit day 5 after infection. ED₅₀ values of compounds of the present invention ranging from ca. 0.2 to 50 mg/kg body weight are obtained.

The compounds of the invention show an surprising overall activity spectrum.

It has, for example, been determined that the MIC (µg/ml) of the compound of Example 1 against, for example *Staphylococcus aureus* (MSSA) is of ca. 0.05 to 0.2; against *Streptococcus pneumoniae* is about 0.0125; against *Klebsiella* is of 0.0125 to 0.8. Surprisingly the compound of Example 1 also shows activity against *Pseudomonas aeruginosa*.

In another aspect the present invention provides a compound of the present invention for use as a pharmaceutical, preferably as an antimicrobial agent, such as an antibiotic.

5 In another aspect the present invention provides the use of a compound of the present invention for the manufacture of a medicament, e.g. a pharmaceutical composition, for the treatment of a microbial diseases, for example diseases mediated by bacterias, such as Escherichia, Enterobacter, Enterococcus, Klebsiella, Streptococcus, Staphylococcus and Pseudomonas.

10 For pharmaceutical use a compound of the present invention includes one or more, preferably one, compounds of the present invention, e.g. a combination of two or more compounds of the present invention.

The compound of example 1 is a preferred compound of the present invention.

15 It has, for example been determined that the MIC ($\mu\text{g/ml}$) of the compound of Example 1 against, for example Klebsiella pneumoniae is of about 0.0125. It is therefore, indicated that for the treatment of microbial diseases, e.g. bacterial diseases, the compounds of the present invention may be administered to larger mammals, for example humans, by similar modes of administration at similar dosages than conventionally used with cefotaxim.

20 In a further aspect the present invention provides a method of treatment of microbial diseases, e.g. which are mediated by bacteria, e.g. diseases mediated by bacterias, such as Escherichia, Enterobacter, Enterococcus, Klebsiella, Streptococcus, Staphylococcus and Pseudomonas, which treatment comprises administering to a subject in need of such
25 treatment an effective amount of a compound of the present invention; e.g. in the form of a pharmaceutical composition.

Treatment includes treatment and prophylaxis.

The compounds of the present invention may be administered in the form of a
30 pharmaceutically acceptable salt, e.g. an acid addition salt or metal salt; or in free form; optionally in the form of a solvate. The compounds of the present invention in the form of a salt exhibit the same order of activity as the compounds of the present invention in free form; optionally in the form of a solvate.

For such treatment, the appropriate dosage will, of course, vary depending upon, for

example, the chemical nature and the pharmacokinetic data of a compound of the present invention employed, the individual host, the mode of administration and the nature and severity of the conditions being treated. However, in general, for satisfactory results in larger mammals, for example humans, an indicated daily dosage is in the range from about 0.1 g to about 2.0 g, of a compound of the present invention; conveniently administered, for example, in divided doses up to four times a day.

A compound of the present invention may be administered by any conventional route, for example enterally, e.g. including nasal, buccal, rectal, oral, administration; parenterally, e.g. including intravenous, intramuscular, subcutaneous administration; or topically; e.g. including epicutaneous, intranasal, intratracheal administration; e.g. in form of coated or uncoated tablets, capsules, injectable solutions or suspensions, e.g. in the form of ampoules, vials, in the form of creams, gels, pastes, inhaler powder, foams, tinctures, lip sticks, drops, sprays, or in the form of suppositories.

The compounds of the present invention may be administered in the form of a pharmaceutically acceptable salt, e.g. an acid addition salt, amine or metal salt; or in free form; optionally in the form of a solvate.

A compound of the present invention may be used for pharmaceutical treatment according to the present invention alone, or in combination with one or more other pharmaceutically active agents. Such other agents include e.g. other antibiotics.


Combinations include fixed combinations, in which two or more pharmaceutically active agents are in the same formulation; kits, in which two or more pharmaceutically active agents in separate formulations are sold in the same package, e.g. with instruction for co-administration; and free combinations in which the pharmaceutically active agents are packaged separately, but instruction for simultaneous or sequential administration are given.

In another aspect the present invention provides a pharmaceutical composition comprising a compound of the present invention in association with at least one pharmaceutical excipient, e.g. appropriate carrier and/or diluent, e.g. including fillers, binders, disintegrators, flow conditioners, lubricants, sugars and sweeteners, fragrances, preservatives, stabilizers, wetting agents and/or emulsifiers, solubilizers, salts for regulating osmotic pressure and/or buffers, e.g. further comprising another pharmaceutically active agent.

Such compositions may be manufactured according, e.g. analogously to a method as conventional, e.g. by mixing, granulating, coating, dissolving or lyophilizing processes. Unit dosage forms may contain, for example, from about 0.5 mg to about 2000 mg, such as 1 mg to about 500 mg.

5

In another aspect the present invention provides a compound of formula



wherein

W_{P2} is CH or N,

10 R_{1P2} is hydrogen, hydroxy, (C_{1-6}) alkoxy, halo (C_{1-6}) alkoxy, hydroxycarbonyl (C_{1-6}) alkoxy or (C_{1-6}) alkyloxycarbonyl (C_{1-6}) alkoxy,

R_{2P2} is hydrogen or an ester moiety,


R_{3P2} is hydrogen, (C_{1-6}) alkyl, allyl or cyclo (C_{1-6}) alkyl,

R_{4P2} is hydrogen or methyl,

15 R_{5P2} , R_{6P2} and R_{7P2} are independently from each other hydrogen, (C_{1-6}) alkyl, (C_{1-6}) alkylcarbonyl, arylcarbonyl, aryl (C_{1-6}) alkylcarbonyl, heteroaryl (C_{1-6}) alkylcarbonyl, (C_{1-6}) alkylsulfonyl, arylsulfonyl or aryl (C_{1-6}) alkylsulfonyl, or R_{7P2} is missing, and $N^+-R_{5P2}R_{6P2}R_{7P2}$ or $N-R_{5P2}R_{6P2}$ can be in o, m or p position, and

20 X_{P2} is $N-R_{8P2}$, O, S, $O-R_{8P2}$ or $S-R_{8P2}$ wherein R_{8P2} is hydrogen, (C_{1-6}) alkyl, cyclo (C_{1-6}) alkyl or aminocyclo (C_{1-6}) alkyl.

In another aspect the present invention provides a compound of formula



wherein

25 W_{P3} is CH or N,

R_{1P3} is hydrogen, hydroxy, (C_{1-6}) alkoxy, halo (C_{1-6}) alkoxy, hydroxycarbonyl (C_{1-6}) alkoxy or (C_{1-6}) alkyloxycarbonyl (C_{1-6}) alkoxy,

- 15 -

R_{2P3} is hydrogen or an ester moiety,


R_{3P3} is hydrogen, (C_{1-8}) alkyl, allyl or cyclo (C_{3-8}) alkyl,

R_{4P3} is hydrogen or methyl,

5 R_{5P3} and R_{6P3} independently from each other are hydrogen, (C_{1-8}) alkyl, (C_{1-8}) alkylcarbonyl, arylcarbonyl, aryl (C_{1-8}) alkylcarbonyl, heteroaryl (C_{1-8}) alkylcarbonyl, (C_{1-8}) alkylsulfonyl, arylsulfonyl or aryl (C_{1-8}) alkylsulfonyl, and

X_{P3} is N- R_{8P3} , O, S, O- R_{8P3} or S- R_{8P3} wherein R_{8P3} is hydrogen, (C_{1-8}) alkyl, cyclo (C_{3-8}) alkyl or aminocyclo (C_{3-8}) alkyl.

10 In another aspect the present invention provides a compound of formula



wherein

W_{P4} is CH or N,

R_{1P4} is hydrogen or O- R_{1P4} ,

15 R_{1P4} is hydrogen, (C_{1-8}) alkyl, halo (C_{1-8}) alkyl or hydroxycarbonyl (C_{1-8}) alkyl,

R_{2P4} is hydrogen or an ester moiety,


R_{3P4} is hydrogen, (C_{1-2}) alkyl, allyl or (C_{3-8}) cycloalkyl,

R_{4P4} is hydrogen or (C_{1-2}) alkyl,

20 R_{5P4} and R_{6P4} independently of each other are hydrogen, (C_{1-8}) alkyl, (C_{1-8}) alkyl-carbonyloxy, arylcarbonyloxy, (C_{1-8}) alkylsulfonyl, arylsulfonyl,

X_{P4} is NH, oxygen or sulfur, and the $CH_2NR_{5P4}R_{6P4}$ group can be in o, m or p position.

In another aspect the present invention provides a compound of formula



25 wherein

W_{P5} is CH or N,

R_{1P5} is hydrogen or O- R_{1P5}

Example 1

3-((E)[[1-trans-(4-Amino-cyclohexylamino)-iminomethyl]-methylhydrazono] methyl)-7-
 {[(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluoromethoxyimino)-acetyl] amino}-3-cephem-4-
 carboxylic acid

5 a) Benzylidene derivative of 3-amino-1-(trans-4-aminocyclohexyl)-3-methyl-guanidine

35 g of the benzylidene derivative of S-methyl-2-methyl-isothiosemicarbazide in the form of a hydrochloride and 32.79 g of trans-1,4-diaminocyclohexane in 300 ml of MeOH are refluxed. The mixture obtained is stirred at RT, a precipitate formed is filtered off and solvent is evaporated. The evaporation residue obtained is treated with 217.5 ml of 2M HCl, a
 10 precipitate formed is filtered off, washed and dried. The volume of the filtrate obtained is brought to about 150 ml, a precipitate is formed is filtered off, washed and dried. The dried, combined precipitates are recrystallized from H₂O and the benzylidene derivative of 3-amino-1-(trans-4-aminocyclohexyl)-3-methyl-guanidine in the form of a monohydrochloride is obtained.

15 b) 3-Amino-1-(trans-4-aminocyclohexyl)-3-methyl-guanidine

From a mixture of 24.74 g of benzylidene derivative of 3-amino-1-(trans-4-aminocyclohexyl)-3-methyl-guanidine in the form of a monohydrochloride in 79.9 ml of 2M HCl, benzaldehyde is distilled off and solvent from the remaining mixture is evaporated. 3-Amino-1-(trans-4-aminocyclohexyl)-3-methyl-guanidine in the form of a dihydrochloride is obtained.

20 c) 3-((E)[[1-trans-(4-amino-cyclohexylamino)-iminomethyl]-methylhydrazono] methyl)-7-[(5-amino-[1,2,4]thiadiazol-3-yl)-(Z)-(fluoromethoxyimino)-acetyl] amino}-3-cephem-4-carboxylic acid


2.78 g of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto(2,1-b)furo(3,4-d)(1,3)-thiazin-6-yl)-2-(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-2-(fluoromethoxyimino) acetic acid amide
 25 are added to a mixture of 2 g of 3-amino-1-(trans-4-aminocyclohexyl)-3-methyl-guanidine in the form of a dihydrochloride in 3.4 ml of 2M HCl and 6.1 ml of DMA and the suspension obtained is stirred at RT. The mixture obtained is poured into AcCN under stirring. A precipitate formed is filtrated off, washed and dried. 3-((E)[[1-trans-(4-Amino-cyclohexylamino)-iminomethyl]-methylhydrazono]methyl)-7-[(5-amino-1,2,4-thiadiazol-3-yl)-
 30 (Z)-(fluoromethoxyimino)-acetyl] amino}-cephem-4-carboxylic acid in the form of a trihydrochloride is obtained.

d) 3-((E)[[1-trans-(4-Amino-cyclohexylamino)-iminomethyl]-methylhydrazono]methyl)-7-[(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluoromethoxyimino)-acetyl]amino}-3-cephem-4-carboxylic acid

10 g of crude 3-[(E)[[1-trans-(4-amino-cyclohexylamino)-iminomethyl]-methylhydrazono]methyl]-7-[(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluoromethoxyimino)-acetyl] amino)-3-cephem-4-carboxylic acid in the form of a trihydrochloride are dissolved in 42 ml of H₂O and subjected to chromatography (LiChroprep RP¹⁸, Merck, grain size 40-63µm). Fractions containing the desired product in the form of a monohydrochloride are combined and optionally lyophilised. 3-[(E)[[1-Trans-(4-amino-cyclohexylamino)-iminomethyl]-methylhydrazono]methyl]-7-[(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluoromethoxyimino)-acetyl]amino)-3-cephem-4-carboxylic acid in the form of a hydrochloride is obtained.

¹H-NMR: 1.30–1.70, m, 4H, CCH₂; 1.80–2.10, m, 4H, CCH₂; 2.88–3.10, m, 1H, NCH; 3.32, s, 3H, NCH₃; 3.42 – 3.70, m, 2H, 1H from SCH₂ and 1H from NCH; 4.25, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 5.28, d, J=5 Hz, 1H, β-lactam; 5.79, d, J=55 Hz, 2H, CH₂F; 5.75, dd, J=5 Hz and 8 Hz, 1H, β-lactam; 8.10, s, 1H, CH=N; 9.84, d, J=8 Hz, 1H, NH.



Analogously to the method as described in Example 1c) and 1d) (purification by chromatography is carried out optionally), but using appropriate starting materials (intermediates), compounds of formula




wherein X, W, R₁, R₃, R₄, R₅, R₆ and R₇ are as defined in TABLE 1 below, are obtained. "P" in TABLE 1 indicates the position of the -NR₅R₆ group in the cyclohexyl ring (o = ortho, m = meta and p = para). R₇ is only present where the compound is in the form of an ammonium salt. In the compounds of examples 2, 20, 22, 27, 30 and 32, the group -NR₄- and the group N-R₅R₆ attached to the cyclohexyl ring are in the cis configuration, in all other examples in the trans configuration. Compounds of EX 1 to 43 are obtained in the form of a hydrochloride and EX 10, 12 and 17 additionally in the form of a trimethylammonium chloride, i.e. the group NR₅R₆ is a group N⁺R₅R₆R₇ Cl⁻.

TABLE 1

EX	W	R ₁	R ₃	R ₄	R ₅	R ₆	X	P
1	N	-OCH ₂ F	CH ₃	H	H	H	NH	p
2	N	-OCH ₂ F	CH ₃	H	H	H	NH	p

EX	W	R ₁	R ₃	R ₄	R ₅	R ₆	X	P
3	N	-OCH ₂ F	ethyl	H	H	H	NH	p
4	CH	OH	CH ₃	H	H	H	NH	p
5	CH	OCH ₃	CH ₃	H	H	H	NH	p
6	N	-OCH ₂ F	allyl	H	H	H	NH	p
7	N	-OCH ₂ F	H	H	H	H	NH	o
8	N	-OCH ₂ F	H	H	H	H	NH	p
9	N	-OCH ₂ F	H	H	CH ₃	CH ₃	NH	p
10	N	-OCH ₂ F	H	H	CH ₃	CH ₃	NH	p
11	N	-OCH ₂ F	H	H	H	H	N-CH ₃	o
12	N	-OCH ₂ F	CH ₃	H	CH ₃	CH ₃	NH	p
13	N	-OCH ₂ F	CH ₃	H		H	NH	p
14	N	-OCH ₂ F	H	CH ₃	CH ₃	H	N-CH ₃	p
15	N	-OCH ₂ F	H	H	H	H	N-CH ₃	p
16	N	-OCH ₂ F	H	H	CH ₃	CH ₃	N-CH ₃	p
17	N	-OCH ₂ F	H	H	CH ₃	CH ₃	N-CH ₃	p
18	N	-OCH ₂ F	H	H	H	H	N-CH ₃	o
19	N	-OCH ₂ F	CH ₃	H	H	H		p
20	N	-OCH ₂ F	CH ₃	H	H	H	NH	m
21	N	-OCH ₂ F	CH ₃	H	H	H	NH	m
22	N	-OCH ₂ F	CH ₃	H	H	H	NH	m
23	N	-OCH ₂ F	CH ₃	H	H	H	NH	m
24	CH	-OC(CH ₃) ₂ (COOH)	CH ₃	H	H	H	NH	p
25	N	-OCH ₂ F	CH ₃	H	H	H	S	p
26	N	-OCH ₂ F	CH ₃	H	H	H	O	p
27	N	-OCH ₂ F	CH ₃	H	H	H	NH	m

EX	W	R ₁	R ₃	R ₄	R ₅	R ₆	X	P
28	N	-OCH ₂ F	CH ₃	H	H	H	N-CH ₃	p
29	N	-OCH ₂ F		H	H	H	NH	p
30	N	-OCH ₂ F	H	CH ₃	H	H	N-CH ₃	p
31	N	-OCH ₂ F	H	CH ₃	H	H	N-CH ₃	p
32	N	-OCH ₂ F	CH ₃	CH ₃	H	H	N-CH ₃	p
33	N	-OCH ₂ F	CH ₃	H	allyl	H	NH	p
34	N	-OCH ₂ F	CH ₃	H	allyl	allyl	NH	p
35	N	-OCH ₂ F	CH ₃	H	i-propyl	H	i-propyl-imino	p
36	N	-OCH ₂ F	CH ₃	H	i-propyl	H	NH	p
37	N	-OCH ₂ F	CH ₃	H	ethyl	H	NH	p
38	N	-OCH ₂ F	CH ₃	H	ethyl	ethyl	NH	p
39	N	-OCH ₂ F	CH ₃	H	n-propyl	H	NH	p
40	N	-OCH ₂ F	CH ₃	H	n-propyl	n-propyl	NH	p
41	N	-OCH ₂ F	CH ₃	H	CH ₃	H	NH	p
42	N	-OCH ₂ F	H	CH ₃	H	H	NH	p
43	N	-OCH ₂ F	CH ₃	CH ₃	H	H	NH	p


Example 44

3-((E)[[1-trans-(4-Acetylamino-cyclohexylamino)-iminomethyl]-methylhydrazono]methyl)-7-[[[(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluoromethoxyimino)-acetyl]amino]-3-cephem-4-carboxylic acid

0.6395 g of N,O-bis-(trimethylsilyl)-acetamid are added to suspension of 0.2579 g of 3-((E)[[1-trans-(4-amino-cyclohexylamino)-iminomethyl]-methylhydrazono]methyl)-7-[[[(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluoromethoxyimino)-acetyl]amino]-3-cephem-4-carboxylic acid in the form of a trihydrochloride in 20 ml of AcCN. To the solution obtained 0.026 ml of acetylchloride are added, the mixture obtained is stirred and treated with 0.115 ml of H₂O. A precipitate is formed, filtrated off and dried. 3-((E)[[1-trans-(4-Acetylamino-cyclohexylamino)-iminomethyl]-methylhydrazono]methyl)-7-{2-(5-amino-[1,2,4]thiadiazol-3-yl)-2-[(Z)-fluoromethoxyimino]-acetyl-amino}-cephem-4-carboxylic acid in the form of a dihydrochloride is obtained. ¹H-NMR: 1.10–1.68, m, 4H, CCH₂; 1.72–2.00, m, 7H, 4H from CCH₂ and 3H

from CH₃; 3.32, s, 3H, NCH₃; 3.40–3.70, m, 3H, 2H from NCH and 1H from SCH₂; 4.56, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 5.27, d, J=5 Hz, 1H, β-lactam; 5.78, d, J=55 Hz, 2H, CH₂F; 5.94, dd, J=5 Hz and 8 Hz, 1H, β-lactam; 8.09, s, 1H, CH=N; 9.85, d, J=8 Hz, 1H, NH.

- 5 Analogously to the method as described in Example 44, but using appropriate starting materials (intermediates), compounds of formula





wherein R₅ is as defined in TABLE 2 below. ¹H-NMR characterisation data of the compounds of examples 45 to 49 are also indicated in TABLE 2. Compounds of EX 45 to 49 are

10 obtained in the form of a hydrochloride.

TABLE 2

EX	R ₅	¹ H-NMR
45		1.32 – 1.72, m, 4H, CCH ₂ ; 1.80 – 2.12, m, 4H, CCH ₂ ; 3.33, s, 3H, NCH ₃ ; 3.40 – 3.90, m, 3H, 2H from NCH and 1H from SCH ₂ ; 4.59, part of the AB-quartet, J=18 Hz, 1H, SCH ₂ ; 5.28, d, J=5 Hz, 1H, β-lactam; 5.79, d, J=55 Hz, 2H, CH ₂ F; 5.95, dd, J=5 Hz and 8 Hz, 1H, β-lactam; 7.32 – 7.58, m, 3H, aromatic-H; 7.70 – 7.90, m, 2H, aromatic-H; 8.10, s, 1H, CH=N; 9.86, d, J=8 Hz, 1H, NH
46		1.25 – 1.70, m, 4H, CCH ₂ ; 1.75 – 2.08, m, 4H, CCH ₂ ; 2.18, s, 3H, CH ₃ ; 3.30, s, 3H, NCH ₃ ; 3.48 – 3.80, m, 3H, 2H from NCH and 1H from SCH ₂ ; 4.54, part of the AB-quartet, J=18 Hz, 1H, SCH ₂ ; 5.28, d, J=5 Hz, 1H, β-lactam; 5.79, d, J=55 Hz, 2H, CH ₂ F; 5.96, dd, J=5 Hz and 8 Hz, 1H, β-lactam; 7.08 – 7.60, m, 4H, aromatic-H; 8.08, s, 1H, CH=N; 9.86, d, J=8 Hz, 1H, NH
47		1.28 – 1.68, m, 4H, CCH ₂ ; 1.75 – 2.02, m, 4H, CCH ₂ ; 3.31, s, 3H, NCH ₃ ; 3.48 – 3.75, m, 3H, 2H from NCH and 1H from SCH ₂ ; 4.20, part of the AB-quartet, J=18 Hz, 1H, SCH ₂ ; 4.50, s, 2H, NCH ₂ ; 5.11, d, J=5 Hz, 1H, β-lactam; 5.66, dd, J=5 Hz and 8 Hz, 1H, β-lactam; 5.78, d, J=55 Hz, 2H, CH ₂ F; 6.82 – 7.02, m, 3H, aromatic-H; 7.22 – 7.40, m, 2H, aromatic-H; 8.08, s, 1H, CH=N; 9.75, d, J=8 Hz, 1H, NH

EX	R ₅	¹ H-NMR
48		1.15 – 1.55, m, 4H, CCH ₂ ; 1.58 – 1.90, m, 4H, CCH ₂ ; 2.05, s, 3H, CH ₃ ; 2.75 – 3.05, m, 1H, NCH; 3.25, s, 3H, NCH ₃ ; 3.32 – 3.68, m, 2H, 1H from NCH and 1H from SCH ₂ ; 4.50, part of the AB-quartet, J=18 Hz, 1H, SCH ₂ ; 5.28, d, J=5 Hz, 1H, β-lactam; 5.77, d, J=55 Hz, 2H, CH ₂ F; 5.96, dd, J=5 Hz and 8 Hz, 1H, β-lactam; 7.65 – 7.90, m, 4H, aromatic-H; 8.05, s, 1H, CH=N; 9.84, d, J=8 Hz, 1H, NH
49		1.15 – 1.68, m, 4H, CCH ₂ ; 1.72 – 2.05, m, 4H, CCH ₂ ; 3.25 – 3.72, m, 8H, 3H from NCH ₃ , 2H from NCH, 2H from NCH ₂ and 1H from SCH ₂ ; 4.20, part of the AB-quartet, J=18 Hz, 1H, SCH ₂ ; 5.12, d, J=5 Hz, 1H, β-lactam; 5.70, dd, J=5 Hz and 8 Hz, 1H, β-lactam; 5.76, d, J=55 Hz, 2H, CH ₂ F; 6.80 – 7.00, m, 2H, thiophenyl-H; 7.30 – 7.40, m, 1H, thiophenyl-H; 8.08, s, 1H, CH=N; 9.76, d, J=8 Hz, 1H, NH

Example 50

3-((E)[[(trans-4-aminocyclohexylimino)methylthiomethyl]methylhydrazono]methyl)-7-
 5 {[(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluoromethoxyimino)-acetyl]amino}-3-cephem-4-
 carboxylic acid

a) 3-((E)[[(trans-4-((1,1-dimethylethoxy)carbonyl)aminocyclohexylimino) methylthio-methyl]-
methylhydrazono]methyl)-7-[[[(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluoromethoxyimino)-
acetyl]amino}-3-cephem-4-carboxylic acid

A solution of 0.103 g of [trans-4-(3-amino-2,3-dimethyl-isothioureido)cyclohexyl]-carbamic
 10 acid tert-butyl ester in 2.5 ml of DMA are added to a solution of 0.144 g of N-(1,4,5a,6-
 tetrahydro-3-hydroxy-1,7-dioxo-3 H,7 H-azeto(2,1-b)furo(3,4-d)(1,3)-thiazin-6-yl)-2-(5-amino-
 1,2,4-thiadiazol-3-yl)-(Z)-2-(fluoromethoxyimino) acetic acid amide in 0.5 ml of DMA, the
 mixture obtained is stirred and 0.165 ml of 2N HCl are added. The mixture obtained is stirred
 at RT, poured onto tert-butyl-methyl-ether and stirred at RT. A precipitate forms and is
 15 filtrated off, washed and dried. 3-((E)[[(trans-4-((1,1-Dimethylethoxy) carbonyl)amino-
 cyclohexylimino)methylthiomethyl]methylhydrazono]methyl)-7-[[[(5-amino-1,2,4-thiadiazol-3-
 yl)-(Z)-(fluoromethoxyimino)-acetyl]amino]-3-cephem-4-carboxylic acid in the form of a
 hydrochloride is obtained.


b) 3-((E)[[(trans-4-aminocyclohexylimino)methylthiomethyl]methylhydrazono]
 20 methyl)-7-[[[(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluoromethoxyimino)-acetyl]amino]-3-
cephem-4-carboxylic acid

2 ml of TFA are added to a cooled suspension of 0.235 g of 3- $\{(\text{E})[[\text{trans-4-}((1,1\text{-dimethylethoxy)carbonyl})\text{amino-cyclohexylimino})\text{methylthiomethyl}]\text{methylhydrazono}]\text{methyl}\}$ -7- $\{[(5\text{-amino-1,2,4-thiadiazol-3-yl})-(\text{Z})-(\text{fluoromethoxyimino})\text{-acetyl}]\text{amino}\}$ -3-cephem-4-carboxylic acid in the form of a hydrochloride in 2 ml of CH_2Cl_2 at 0°C . The solution obtained is stirred and solvent is evaporated. The evaporation residue obtained is treated with H_2O and a precipitate formed is filtrated off. The filtrate obtained is lyophilized and the lyophilisation residue obtained is treated with H_2O and 2N HCl. The solution obtained is subjected to chromatography (LiChroprep RP¹⁸) and fractions containing the desired compound are combined and lyophilised. 3- $\{(\text{E})[[\text{trans-4-Aminocyclohexylimino})\text{methylthiomethyl}]\text{methylhydrazono}]\text{methyl}\}$ -7- $\{[(5\text{-amino-1,2,4-thiadiazol-3-yl})-(\text{Z})-(\text{fluoromethoxyimino})\text{-acetyl}]\text{amino}\}$ -3-cephem-4-carboxylic acid in the form of a hydrochloride is obtained. $^1\text{H-NMR}$: 1.30–1.78, m, 4H, CCH_2 ; 1.88 – 2.12, m, 4H, CCH_2 ; 2.64, s, 3H, SCH_3 ; 2.90–3.18, m, 1H, NCH ; 3.52–3.72, m, 4H, 3H from NCH_3 and 1H from SCH_2 ; 3.88–4.12, m, 1H, NCH ; 4.32, part of the AB-quartet, $J=18\text{ Hz}$, 1H, SCH_2 ; 5.30, d, $J=5\text{ Hz}$, 1H, β -lactam; 5.77, d, $J=55\text{ Hz}$, 2H, CH_2F ; 5.98, dd, $J=5\text{ Hz}$ and 8 Hz , 1H, β -lactam; 8.38, s, 1H, CH=N ; 9.88, d, $J=8\text{ Hz}$, 1H, NH.

Example 51

3- $\{(\text{E})[[1\text{-}(3\text{-}\{\text{Aminomethyl}\}\text{cyclohexylmethyl})\text{-iminomethyl}]\text{-methylhydrazono}]\text{methyl}\}$ -7- $\{[(5\text{-amino-1,2,4-thiadiazol-3-yl})-(\text{Z})-(\text{fluoromethoxyimino})\text{-acetyl}]\text{amino}\}$ -3-cephem-4-carboxylic acid (in the form of a hydrochloride) is obtained according to the method as described in Example 1, but using the appropriate starting materials. $^1\text{H-NMR}$: 0.40 – 1.92, m, 10H, 8H from CCH_2 and 2H from CCH ; 2.58 – 2.85, m, 2H, NCH_2 ; 3.05 – 3.28, m, 2H, NCH_2 ; 3.34, s, 3H, NCH_3 ; 3.50 and 4.59, AB-quartet, $J=18\text{ Hz}$, 2H, SCH_2 ; 5.28, d, $J=5\text{ Hz}$, 1H, β -lactam; 5.78, d, $J=55\text{ Hz}$, 2H, CH_2F ; 5.95, dd, $J=5\text{ Hz}$ and 8 Hz , 1H, β -lactam; 8.10, s, 1H, CH=N ; 9.84, d, $J=8\text{ Hz}$, 1H, NH.

According to the method as described in Example 1, but using appropriate starting materials (intermediates), compounds of formula IA wherein W is N, R_2 is hydrogen, R_3 is methyl, R_4 , R_5 and R_6 are hydrogen, $n = 1$, $m = 1$,



is cyclohexyl and R_1 is as described in TABLE 3 below, are obtained. "P" in TABLE 3 indicates the position of the $-(\text{CH}_2)_m\text{-NR}_5\text{R}_6$ group in the cyclohexyl ring ($m = \text{meta}$

and p = para). In the compound of example 52 the group -NR₄- and the group -(CH₂)_m-NR₅R₆ attached to the cyclohexyl ring are in the cis configuration, in all other examples in the trans configuration. ¹H-NMR characterisation data of the compounds of examples 52 to 54 are also indicated in TABLE 3. Compounds of EX 52 to 54 are obtained in the form of a hydrochloride.

TABLE 3

EX	R ₁ /P	¹ H-NMR
52	CH ₂ F m	0.50-2.08, m, 8H from CCH ₂ ; 2.55-2.90, m, 2H, NCH ₂ ; 3.00 - 3.38, m, 2H, NCH ₂ ; 3.34, s, 3H, NCH ₃ ; 3.49 and 4.59, AB-quartet, J=18 Hz, 2H, SCH ₂ ; 5.28, d, J=5 Hz, 1H, β-lactam; 5.77, d, J=55 Hz, 2H, CH ₂ F; 5.96, dd, J=5 Hz and 8 Hz, 1H, β-lactam; 8.10, s, 1H, CH=N; 9.84, d, J=8 Hz, 1H, NH
53	CH ₂ F p	0.70 - 1.10, m, 4H, CCH ₂ ; 1.40 - 1.90, m, 6H, 4H from CCH ₂ and 2H from CCH; 2.58 - 2.75, m, 2H, NCH ₂ ; 3.10 - 3.30, m, 2H, NCH ₂ ; 3.34, s, 3H, NCH ₃ ; 3.50 and 4.60, AB-quartet, J=18 Hz, 2H, SCH ₂ ; 5.28, d, J=5 Hz, 1H, β-lactam; 5.77, d, J=55 Hz, 2H, CH ₂ F; 5.94, dd, J=5 Hz and 8 Hz, 1H, β-lactam; 8.09, s, 1H, CH=N; 9.84, d, J=8 Hz, 1H, NH
54	OH p	0.70-1.12, m, 4H, CCH ₂ ; 1.40 - 1.92, m, 6H, 4H from CCH ₂ and 2H from CCH; 2.56 - 2.78, m, 2H, NCH ₂ ; 3.08 - 3.30, m, 2H, NCH ₂ ; 3.34, s, 3H, NCH ₃ ; 3.55 and 4.57, AB-quartet, J=18 Hz, 2H, SCH ₂ ; 5.14, d, J=5 Hz, 1H, β-lactam; 5.72, dd, J=5 Hz and 8 Hz, 1H, β-lactam; 6.66, s, 1H, CH thiazol; 7.14, b, 2H, NH; 8.11, s, 1H, CH=N; 9.82, d, J=8 Hz, 1H, NH

According to the method as described in Example 1, but using appropriate starting materials the compounds of Examples 55 to 58 are obtained:

10 Example 55

3-((E)[[1-(3-(aminobenzylamino)-iminomethyl)-methylhydrazono]-methyl]-7-(((5-amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluoromethoxyimino)-acetyl)-amino)-3-cephem-4-carboxylic acid (in the form of a hydrochloride)

¹H-NMR: 3.38, s, 3H, NCH₃; 3.52, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 4.50 - 4.75, m, 3H, 2H from NCH₂ and 1H from SCH₂; 5.29, d, J=5 Hz, 1H, β-lactam; 5.76, d, J=55 Hz, 2H, CH₂F; 5.95, dd, J=5 Hz and 8 Hz, 1H, β-lactam; 7.25 - 7.60, m, 4H, aromatic H; 8.17, s, 1H, CH=N; 9.75, d, J=8 Hz, 1H, NH

Example 56


3-((E)[[1-[3-(aminomethyl)benzylamino]-iminomethyl]-methylhydrazono]methyl]-7-(((5-amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluoromethoxyimino)-acetyl)amino)-3-cephem-4-carboxylic acid (in the form of a hydrochloride)

¹H-NMR: 3.41, s, 3H, NCH₃; 3.52, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 3.88 - 4.12, m, 2H, NCH₂; 4.40 - 4.80, m, 3H, 2H from NCH₂ and 1H from SCH₂; 5.28, d, J=5 Hz, 1H, β-

lactam; 5.78, d, $J=55$ Hz, 2H, CH_2F ; 5.96, dd, $J=5$ Hz and 8 Hz, 1H, β -lactam; 7.22 – 7.58, m, 4H, aromatic H; 8.14, s, 1H, $\text{CH}=\text{N}$; 9.84, d, $J=8$ Hz, 1H, NH

Example 57

Compound of formula IA in the form of a hydrochloride wherein




5 is phenyl, X is NH, R_1 is OCH_2F , R_3 is CH_3 , $\text{R}_2, \text{R}_4, \text{R}_5, \text{R}_6$ are H, $n=1$, $m=1$ and the $-(\text{CH}_2)_m-\text{NR}_5\text{R}_6$ group in the phenyl ring is in the para position.

$^1\text{H-NMR}$: 3.38, s, 3H, NCH_3 ; 3.52, part of the AB-quartet, $J=18$ Hz, 1H, SCH_2 ; 3.90 – 4.12, m, 2H, NCH_2 ; 4.50 – 4.80, m, 3H, 2H from NCH_2 and 1H from SCH_2 ; 5.28, d, $J=5$ Hz, 1H, β -lactam; 5.78, d, $J=55$ Hz, 2H, CH_2F ; 5.96, dd, $J=5$ Hz and 8 Hz, 1H, β -lactam; 7.28 – 7.60, m, 4H, aromatic H; 8.14, s, 1H, $\text{CH}=\text{N}$; 9.84, d, $J=8$ Hz, 1H, NH.

Example 58

Compound of formula IA in the form of a hydrochloride wherein



15 is phenyl, X is NH, R_1 is OH, R_3 is CH_3 , $\text{R}_2, \text{R}_4, \text{R}_5, \text{R}_6$ are H, $n=1$, $m=1$ and the $-(\text{CH}_2)_m-\text{NR}_5\text{R}_6$ in the phenyl ring is in the para position.

$^1\text{H-NMR}$: 3.37, s, 3H, NCH_3 ; 3.57, part of the AB-quartet, $J=18$ Hz, 1H, SCH_2 ; 3.90 – 4.10, m, 2H, NCH_2 ; 4.45 – 4.75, m, 3H, 2H from NCH_2 and 1H from SCH_2 ; 5.15, d, $J=5$ Hz, 1H, β -lactam; 5.74, dd, $J=5$ Hz and 8 Hz, 1H, β -lactam; 6.88, s, 1H, CH thiazol; 7.20 – 7.55, m, 4H, aromatic H; 8.15, s, 1H, $\text{CH}=\text{N}$; 9.78, d, $J=8$ Hz, 1H, NH.

INTERMEDIATES

Example A

3-Amino-1-(trans-4-aminocyclohexyl)-guanidine

a) [trans-4-(3-Ethoxycarbonyl-thioureido)cyclohexyl]carbamic acid tert-butyl ester

25 To a solution of 1.10 g of (4-amino-cyclohexyl)-carbamic acid tert-butyl ester in 25 ml of EtAc 0.58 ml of ethoxycarbonyl-isothiocyanat are added and the mixture obtained is stirred at RT. The precipitate formed is filtered and washed with diethylether.

[trans-4-(3-Ethoxycarbonyl-thioureido)cyclohexyl]carbamic acid tert-butyl ester is obtained.

b) (trans-4-Thioureido-cyclohexyl)-carbamic acid tert-butyl ester

7.4 ml of 4M NaOH are added to a suspension of 1.69 g of [trans-4-(3-ethoxycarbonyl-thioureido)cyclohexyl]carbamic acid tert-butyl ester in 10 ml of H₂O and 15 ml of EtOH. The mixture obtained is kept at 90° for 30 minutes at RT. The precipitate formed is filtered and washed with diethylether. (trans-4-Thioureido-cyclohexyl)-carbamic acid tert-butyl ester is obtained.

c) [trans-4-(2-Methyl-isothioureido)-cyclohexyl]-carbamic acid tert-butyl ester

A mixture of 1.19 g of (trans-4-thioureido-cyclohexyl)-carbamic acid tert-butyl ester and 0.41 ml of methyl iodide in 50 ml of MeOH is stirred at RT. From the mixture obtained solvent is evaporated and [trans-4-(2-methyl-isothioureido)-cyclohexyl]-carbamic acid tert-butyl ester in the form of a hydroiodide is obtained.

d) [trans-4-(2-Methyl-isothioureido)-cyclohexyl]-carbamic acid tert-butyl ester

40 ml of a strong basic ion exchanger in chloride form (Amberlite IRA 400 (Cl)^R) are added to a suspension of 2.06 g of [trans-4-(2-methyl-isothioureido)-cyclohexyl]-carbamic acid tert-butyl ester in the form of a hydroiodide in 50 ml of H₂O. The mixture obtained is stirred at RT, the ion exchanger is filtrated off and the filtrate obtained is lyophilised. [trans-4-(2-Methyl-isothioureido)-cyclohexyl]-carbamic acid tert-butyl ester in the form of a hydrochloride is obtained.

e) [trans-4-((Hydrazino)iminomethyl)aminocyclohexyl]-carbamic acid tert-butyl ester




0.183 ml of hydrazine monohydrate are added to a solution of 1.11 g of [trans-4-(2-methyl-isothioureido)-cyclohexyl]-carbamic acid tert-butyl ester in 50 ml of EtOH, the mixture obtained is refluxed and solvent is evaporated. [trans-4-(Hydrazino)iminomethyl)aminocyclohexyl]-carbamic acid tert-butyl ester in the form of a hydrochloride is obtained.

f) 3-Amino-1-(trans-4-aminocyclohexyl)-guanidine

A mixture of 1.15 g of [trans-4-(hydrazino)iminomethyl)-aminocyclohexyl]-carbamic acid tert-butyl ester in the form of a hydrochloride and 4.2 ml of 5.4M HCl (in MeOH) in 50 ml of MeOH is stirred at RT. The volume of the mixture is reduced and a precipitate formed is filtrated off, washed and dried. 3-Amino-1-(trans-4-aminocyclohexyl)-guanidine in the form of a dihydrochloride is obtained. ¹H-NMR: 1.10 – 1.60, m, 4H, CCH₂; 1.72 – 2.12, m, 4H, CCH₂; 2.75 – 3.08, m, 1H, NCH; 3.30 – 3.60, m, 1H, NCH; 8.30, b, 3H, NH.

According to the method as set out in Example A, but using appropriate starting materials, the compounds of Examples A2 to A4 of TABLE 4 below in the form of a hydrochloride are obtained. ¹H-NMR data are also set out in TABLE 4.

TABLE 4

EX	Compound of formula	¹ H-NMR
A2		1.08 – 2.20, m, 8H, CCH ₂ ; 3.00 – 3.28, m, 1H, NCH; 3.60 – 3.88, m, 1H, NCH; 7.72, b, 2H, NH; 8.48, b, 3H, NH
A3		1.00 – 2.20, m, 8H, CCH ₂ ; 2.78, s, 3H, NCH ₃ ; 3.05 – 3.32, m, 1H, NCH; 3.60 – 3.85, m, 1H, NCH; 8.50, b, 3H, NH
A4		1.25 – 1.65, m, 4H, CCH ₂ ; 1.70 – 2.20, m, 4H, CCH ₂ ; 2.70 – 3.08, m, 4H, 3H from NCH ₃ and 1H from NCH; 3.35 – 3.65, m, 1H, NCH; 8.35, b, 3H, NH

Example B**3-Amino-2-(trans-4-dimethylaminocyclohexyl)-1-methyl-guanidine****a) 1-(trans-4-Dimethylaminocyclohexyl)-3-methyl-thiourea**

- 5 0.90 g of Methyl-isothiocyanate are added to a solution of 1.74 g of trans-4-dimethylaminocyclohexanamine in 50 ml of EtAc. The mixture obtained is stirred at RT, solvent is evaporated and 1-(4-dimethylaminocyclohexyl)-3-methyl-thiourea is obtained.

b) 1-(trans-4-Dimethylaminocyclohexyl)-2,3-dimethyl-isothiurea



- 10 A mixture of 0.50 g of 1-(4-dimethylaminocyclohexyl)-3-methyl-thiourea in 10 ml of MeOH, 1.16 ml of 2M HCl (in MeOH) and 0.36 g of methyl iodide is stirred at RT. From the mixture obtained solvent is evaporated and the evaporation residue obtained is treated with H₂O. 10 ml of a strong basic ion exchanger in chloride form (Amberlite IRA 400 (Cl)^R) are added to the aqueous mixture obtained and the mixture obtained is stirred at RT. A precipitate obtained is filtrated off and the filtrate obtained is lyophilized. 1-(trans-4-Dimethylaminocyclohexyl)-2,3-dimethyl-isothiurea in the form of a hydrochloride is obtained.

c) 3-Amino-2-(trans-4-dimethylaminocyclohexyl)-1-methyl-guanidine

- 15 A solution of 0.71 g of 1-(4-dimethylaminocyclohexyl)-2,3-dimethyl-isothiurea in the form of a hydrochloride in 40 ml of EtOH absolute and 0.126 ml of hydrazine monohydrate is refluxed. From the mixture obtained solvent is evaporated and 3-amino-2-(trans-4-dimethylaminocyclohexyl)-1-methyl-guanidine in the form of a dihydrochloride is obtained.
- 20 ¹H-NMR: 1.12 – 1.55, m, 4H, CCH₂; 1.75 – 1.98, m, 4H, CCH₂; 2.30, b, 6H, NCH₃; 2.70, s, 3H, NCH₃; 3.20 – 3.80, m, 2H, NCH.

According to the method as set out in Example B, but using appropriate starting materials, the compounds of Example B2 and B3 of TABLE 5 below in the form of a hydrochloride are obtained. ¹H-NMR-data of the compounds obtained are also set out in TABLE 5.

TABLE 5

EX	Compound of formula	¹ H-NMR
B2		(D ₂ O) 1.22 – 1.70, m, 4H, CCH ₂ ; 1.90 – 2.28, m, 4H, CCH ₂ ; 2.70, b, 6H, NCH ₃ ; 2.95–3.45, m, 2H, NCH
B3		1.10 – 1.88, 6H, CCH ₂ ; 1.90 – 2.18, m, 2H, CCH ₂ ; 2.37, s, 3H, NCH ₃ ; 2.76, s, 3H, NCH ₃ ; 2.83, s, 3H, NCH ₃ ; 3.32 – 3.62, m, 2H, NCH

Example C

[trans-4-((Hydrazino)methyliminomethyl)aminocyclohexyl]-trimethylammonium-chloride


a) [trans-4-(2,3-Dimethyl-isothioureido)-cyclohexyl]-trimethylammoniumchloride

A mixture of 0.50 g of 1-(4-dimethylamino-cyclohexyl)-3-methyl-thiourea in 20 ml of MeOH and 0.36 ml of methyl iodide is stirred at RT. The mixture obtained is refluxed and solvent is evaporated. A residue formed is treated with H₂O, the aqueous mixture obtained is stirred in the presence of a strong basic ion exchanger in chloride form (Amberlite IRA 400 (Cl)^R), filtered and the filtrate obtained is subjected to lyophilisation. [trans-4-(2,3-Dimethyl-isothioureido)-cyclohexyl]-trimethylammoniumchloride is obtained.

b) [trans-4-((Hydrazino)methyliminomethyl)aminocyclohexyl]- trimethylammoniumchloride

A solution of [trans-4-(2,3-dimethyl-isothioureido)-cyclohexyl]-trimethylammoniumchloride in EtOH and 0.118 ml of hydrazine monohydrate is refluxed and from the mixture obtained solvent is evaporated. [trans-4-((Hydrazino)methyliminomethyl)aminocyclohexyl]-trimethylammoniumchloride is obtained in the form of a hydrochloride. ¹H-NMR: 1.40–1.70, m, 4H, CCH₂; 1.82–2.30, m, 4H, CCH₂; 2.80, s, 3H, NCH₃; 3.05, b, 9H, NCH₃; 3.30–3.50, m, 1H, NCH; 3.60–3.80, m, 1H, NCH.

According to the method as set out in Example C, but using appropriate starting materials, the compound of formula



in the form of a hydrochloride is obtained. $^1\text{H-NMR}$: 1.18 – 1.70, m, 4H, CCH_2 ; 1.88 – 2.30, m, 4H, CCH_2 ; 3.05, b, 9H, NCH_3 ; 3.20 – 3.68, m, 2H, NCH .

5 Example D

3-Amino-bis-1,2-(trans-4-aminocyclohexyl)-3-methyl-guanidine

a) Benzylidene derivative of 3-amino-bis-1,2-(trans-4-aminocyclohexyl)-3-methyl-guanidine

S-methyl-2-methyl-isothiosemicarbazide is reacted with trans-1,4-diaminocyclohexane according to the method of Example 1a). Beside 3-amino-1-(trans-4-aminocyclohexyl)-3-methyl-guanidine in the form of a monohydrochloride, a side product is obtained which is purified by column chromatography (Li Chroprep RP-18^R, Merck). The benzylidene derivative of 3-amino-bis-1,2-(trans-4-aminocyclohexyl)-3-methyl-guanidine in the form of a dihydrochloride is obtained.









15 b) 3-Amino-bis-1,2-(trans-4-aminocyclohexyl)-3-methyl-guanidine in the form of a trihydrochloride


is obtained from the benzylidene derivative of 3-amino-bis-1,2-(trans-4-aminocyclohexyl)-3-methyl-guanidine in the form of a dihydrochloride according to the method of Example 1b). $^1\text{H-NMR}$: (D_2O) 1.20 – 1.60, m, 8H, CCH_2 ; 1.80 – 2.18, m, 8H, CCH_2 ; 2.95 – 3.20, 5H, 3H from NCH_3 and 2H from NCH ; 3.22 – 3.48, m, 2H, NCH .

Analogously as described in Example D, but using appropriate starting materials the compounds of Examples D1 to D10 as set out in TABLE 6 below in the form of a hydrochloride are obtained. $^1\text{H-NMR}$ data are also set out in TABLE 6.

TABLE 6

EX	Compound of formula	$^1\text{H-NMR}$
D1		1.10 – 2.25, m, 8H, CCH_2 ; 2.88 – 3.12, m, 1H, NCH ; 3.20, s, 3H, NCH_3 ; 3.52 – 3.85, m, 1H, NCH ; 7.75, b, 2H, NH ; 8.40, b, 3H, NH

D2		(D ₂ O) 1.25 – 1.60, m, 4H, CCH ₂ ; 1.82 – 2.18, m, 4H, CCH ₂ ; 3.00 – 3.20, 4H, 3H from NCH ₃ and 1H from NCH; 3.22 – 3.45, m, 1H, NCH
D3		(D ₂ O) 1.50 – 1.90, m, 8H, CCH ₂ ; 3.09, s, 3H, NCH ₃ ; 3.20 – 3.40, m, 1H, NCH; 3.50 – 3.68, m, 1H, NCH
D4		
D5		(D ₂ O) 0.50–2.00, m, 10H, 8H from CCH ₂ and 2H from CCH; 2.65–2.85, m, 2H, NCH ₂ ; 2.92–3.30, m, 5H, 3H from NCH ₃ and 2H from NCH ₂
D6		(D ₂ O) 0.50–2.00, m, 10H, 8H from CCH ₂ and 2H from CCH; 2.80–2.95, m, 2H; NCH ₂ ; 2.98–3.25, m, 5H, 3H from NCH ₃ and 2H from NCH ₂
D7		(D ₂ O) 0.72–1.08, m, 4H, CCH ₂ ; 1.32–1.88, m, 6H, 4H from CCH ₂ and 2H from CCH; 2.62–2.85, m, 2H, NCH ₂ ; 2.90–3.25, m, 5H, 3H from NCH ₃ and 2H from NCH ₂
D8		(D ₂ O) 3.17, s, 3H, NCH ₃ ; 4.09, b, 2H, NCH ₂ ; 4.42, b, 2H, NCH ₂ ; 7.20–7.48, m, 4H, arom. H
D9		(D ₂ O) 3.18, s, 3H, NCH ₃ ; 4.09, b, 2H, NCH ₂ ; 4.43, b, 2H, NCH ₂ ; 7.20–7.55, m, 4H, arom. H

**Example E****[trans-4-((1-Methylhydrazino)iminomethyl)aminocyclohexyl]-trimethyl-ammoniumchloride****5 a) Benzylidene derivative of 3-amino-1-(trans-4-aminocyclohexyl)-3-methyl-guanidine**

The pH of a solution of 5 g of the benzylidene derivative of 3-amino-1-(trans-4-aminocyclohexyl)-3-methyl-guanidine in the form of a monohydrochloride in H₂O is adjusted to pH 13.6 by addition of 8N NaOH. The mixture obtained is extracted with CH₂Cl₂. The organic phase obtained is dried and solvent is evaporated. The benzylidene derivative of 3-amino-1-(trans-4-aminocyclohexyl)-3-methyl-guanidine is obtained.

10 b) Benzylidene derivative of [trans-4-((1-methylhydrazino)iminomethyl))-aminocyclohexyl]-trimethylammoniumchloride

1.295 g of methyl iodide in 10 ml of AcCN are added to a solution of 1 g of the benzylidene derivative of 3-amino-1-(trans-4-aminocyclohexyl)-3-methyl-guanidine in AcCN. The mixture obtained is refluxed and stirred at RT. Solvent is evaporated, the evaporation residue obtained is treated with H₂O and with 20 ml of a strong basic ion exchanger in chloride form. A suspension formed is stirred at RT, filtered and the filtrate obtained is subjected to lyophilisation. The lyophilizate obtained is treated with H₂O, the pH of the solution obtained is adjusted with 8N NaOH to pH 13.4, the mixture obtained is extracted with CH₂Cl₂, the aqueous phase obtained is adjusted with 8N HCl to pH 2 and the mixture obtained is lyophilised. The lyophilisate obtained is dissolved in H₂O and subjected to chromatography (Li-Chroprep RP-18^R, grain size 40-63 µm, Merck). Fractions containing the desired product are collected and lyophilized. The benzylidene derivative of [trans-4-((1-methylhydrazino)-(iminomethyl))aminocyclohexyl]-trimethylammoniumchloride in the form of a hydrochloride is obtained.

25 c) [trans-4-((1-Methylhydrazino)iminomethyl)aminocyclohexyl]-trimethyl-ammoniumchloride hydrochloride

A mixture of the benzylidene derivative of [trans-4-((1-methylhydrazino)(iminomethyl))-aminocyclohexyl]-trimethylammoniumchloride in 1.7 ml of 2N HCl and H₂O is treated by steam distillation. From the mixture obtained solvent is evaporated. [trans-4-((1-Methylhydrazino)iminomethyl) aminocyclohexyl]-trimethylammoniumchloride in the form of a

hydrochloride is obtained. ¹H-NMR: 1.35–1.72, m, 4H, CCH₂; 1.82–2.30, m, 4H, CCH₂; 3.05, b, 9H, NCH₃; 3.20, s, 1H, NCH₃; 3.30 – 3.72, m, 2H, NCH; 7.45, d, J=4 Hz, 1H, NH; 7.74, b, 2H, NH.

5 Example F

3-Amino-1-(trans-4-aminocyclohexyl)-3-ethyl-guanidine

a) Benzylidene derivative of [trans-4-((hydrazino)iminomethyl)aminocyclohexyl]-1-N-formamide

A mixture of 5.5 ml of acetic anhydride and 11.2 ml of formic acid is stirred at 0° and a solution of 5.04 g of benzylidene derivative of 3-amino-1-(trans-4-aminocyclohexyl)-guanidine in 5.6 ml of formic acid are added. From the mixture obtained solvent is evaporated. The evaporation residue obtained is treated with H₂O and the pH of a solution formed is adjusted to 13.02 with 2N NaOH. A precipitate formed is filtered off, washed and dried. The benzylidene derivative of [trans-4-((hydrazino)iminomethyl)aminocyclohexyl]-1-N-formamide is obtained.

b) Benzylidene derivative of [trans-4-((1-ethylhydrazino)iminomethyl)aminocyclohexyl]-1-N-formamide


A mixture of 0.28 ml of ethyl iodide and of a solution of 0.5 g of the benzylidene derivative of [trans-4-((1-hydrazino)(iminomethyl)aminocyclohexyl)-N-formamide is refluxed. The mixture obtained is kept overnight at RT and further ethyl iodide is added. The mixture obtained is refluxed and the mixture obtained again is kept at RT. A precipitate forms, which is filtered off and dried. The benzylidene derivative of [trans-4-((1-ethylhydrazino)iminomethyl)aminocyclohexyl]-1-N-formamide in the form of a hydroiodide is obtained.

c) 3-Amino-1-(trans-4-aminocyclohexyl)-3-ethyl-guanidine

A suspension of 0.34 g of the benzylidene derivative of [trans-4-((1-ethylhydrazino)iminomethyl)aminocyclohexyl]-1-N-formamide in the form of a hydroiodide in 10 ml of H₂O and 10 ml of strong basic ion exchanger in chloride form is stirred. The mixture obtained is filtrated and the filtrate obtained is treated with 2 ml of 2N HCl, benzaldehyde and formic acid are distilled off and solvent is evaporated. 3-Amino-1-(trans-4-aminocyclohexyl)-3-ethyl-guanidine in the form of a dihydrochloride is obtained. ¹H-NMR: (D₂O) 0.88 – 1.75, m, 6H, 4H from CCH₂ and 3H from CCH₃; 1.80 – 2.35, m, 4H, CCH₂; 2.90 – 3.70, m, 4H, 2H from NCH₂ and 2H from NCH.

According to the method as described in Example F, but using appropriate starting materials the compound of formula

- 33 -



in the form of a hydrochloride is obtained. ¹H-NMR: (D₂O) 1.20 – 1.65, m, 4H, CCH₂; 1.80 – 2.22, m, 4H, CCH₂; 3.00 – 3.20, m, 1H, NCH; 3.22 – 3.52, m, 1H, NCH; 3.88 – 4.20, m, 2H, NCH₂; 4.98 – 5.40, m, 2H, C=CH₂; 5.55 – 5.88, m, 1H, CH=C.

5

Example G**4-Amino-N-[(trans-4-((1-methylhydrazino)iminomethyl)aminocyclohexyl)-benzene-sulfonamide]****a) Benzylidene derivative of N-[4-[(trans-4-((1-methylhydrazino)iminomethyl)]-aminocyclohexyl)sulfamoyl]-phenyl]acetamide**

10

2.37 ml of N,O-bis-(trimethylsilyl)-acetamide are added to a suspension of 0.5 g of the benzylidene derivative of 3-amino-1-(trans-4-aminocyclohexyl)-3-methyl-guanidine in AcCN. A solution obtained is treated with 0.378 g of 4-acetylamino-benzenesulfonyl chloride and stirred at RT. To the mixture obtained 3.49 ml of H₂O/AcCN are added, a precipitate formed is filtrated off, washed and dried. The benzylidene derivative of N-[4-[(trans-4-((1-methyl-

15

b) 4-Amino-N-[(trans-4-((1-methylhydrazino)iminomethyl)aminocyclohexyl)]benzene-sulfonamide

A mixture of 0.62 g of the benzylidene derivative of N-[4-[(trans-4-((1-methylhydrazino)imino-methyl)]aminocyclohexyl)sulfamoyl]phenyl]acetamide is treated with 3.4 ml of 1N HCl and H₂O. The aqueous solution obtained is concentrated and dried. 4-Amino-N-[(trans-4-((1-methylhydrazino)iminomethyl)aminocyclohexyl)-benzene-sulfonamide in the form of a dihydrochloride is obtained. ¹H-NMR: 1.10 – 1.40, m, 4H, CCH₂; 1.50 – 1.80, m, 4H, CCH₂; 2.65 – 2.90, m, 1H, NCH; 3.10, s, 3H, NCH₃; 3.20 – 3.50, m, 1H, NCH; 6.85, d, J=4 Hz, 2H, aromatic-H; 7.52, d, J=4 Hz, 2H, aromatic-H.

25

Example H**3-Amino-1-(trans-4-aminocyclohexyl)-2,3-dimethyl-guanidine****a) [trans-4-(3-Amino-3-methyl-thioureido)cyclohexyl]carbamic acid tert-butylester**

0.49 ml of methylhydrazine are added to a solution of 2 g of (trans-4-isothiocyanate-cyclohexyl)carbamic acid tert-butylester. The mixture obtained is stirred at RT and petrolether is added. A precipitate formed is filtrated off, washed and dried. [trans-4-(3-Amino-3-methyl-thioureido) cyclohexyl]carbamic acid tert-butylester is obtained.

5 b) [trans-4-(3-Amino-2,3-dimethyl-isothioureido)cyclohexyl]-carbamic acid tert-butylester

A suspension of 1.17 g of [trans-4-(3-amino-3-methyl-thioureido)cyclohexyl]carbamic acid tert-butylester in 30 ml of MeOH is treated with 0.34 ml of methyl iodide, the mixture obtained is refluxed and solvent is evaporated. The evaporation residue obtained is suspended in H₂O and treated with a strong basic ion exchanger in chloride form. The mixture obtained is stirred at RT, the ion exchanger is filtered off and the filtrate obtained is lyophilised. [trans-4-(3-Amino-2,3-dimethyl-isothioureido) cyclohexyl]carbamic acid tert-butylester in the form of a hydrochloride is obtained.

10 c) Benzylidene derivative of [trans-4-(3-amino-2,3-dimethyl-isothioureido)cyclohexyl]-carbamic acid tert-butyl ester

15 1.3 ml of 2N HCl and 0.15 ml of benzaldehyde are added to a solution of 0.40 g of [trans-4-(3-amino-2,3-dimethyl-isothioureido)cyclohexyl]carbamic acid tert-butylester in the form of a hydrochloride in 20 ml of H₂O and 30 ml of AcCN. The mixture obtained is stirred, AcCN is evaporated and a solution obtained is extracted with ether. The pH of the aqueous phase obtained is adjusted to pH 7 and a precipitate formed is filtrated off, washed and dried. The benzylidene derivative of [trans-4-(3-amino-2,3-dimethyl-isothioureido)cyclohexyl]carbamic acid tert-butylester in the form of a hydrochloride is obtained.

20 d) Benzylidene derivative of [trans-4-(1-methylhydrazino)(methyliminomethyl)amino-cyclohexyl]carbamic acid tert-butylester

A suspension of 0.2 g of the benzylidene derivative of [trans-4-(3-amino-2,3-dimethyl-isothioureido)cyclohexyl]carbamic acid tert-butylester in the form of a hydrochloride is treated with 0.126 ml of methylamine (33% in EtOH abs.) and stirred. From the mixture obtained solvent is evaporated and the benzylidene derivative of [trans-4-(1-methylhydrazino)(methyl iminomethyl)aminocyclohexyl]carbamic acid tert-butylester is obtained.


25 e) Benzylidene derivative of 3-amino-1-(trans-4-aminocyclohexyl)-2,3-dimethyl-guanidine

30 10 ml of TFA are added to a solution of 0.2 g of the benzylidene derivative of [trans-4-(1-methylhydrazino)(methyl-iminomethyl)aminocyclohexyl]carbamic acid tert-butylester in 10 ml of CH₂Cl₂ at 0°. The mixture obtained is stirred at RT, solvent is evaporated and the benzylidene derivative of 3-amino-1-(trans-4-aminocyclohexyl)-2,3-dimethyl-guanidine in the form of a trifluoroacetate is obtained.


f) 3-Amino-1-(trans-4-aminocyclohexyl)-2,3-dimethyl-guanidine

1.6 ml of 1N HCl are added to a solution of 0.2 g of the benzylidene derivative of 3-amino-1-(trans-4-amino-cyclohexyl)-2,3-dimethyl-guanidine in the form of a trifluoroacetate in H₂O (benzaldehyde is split off). The volume of the mixture obtained is concentrated and 20 ml of strong basic ion exchanger in chloride form are added. The mixture obtained is stirred, filtrated and solvent from the filtrate obtained is evaporated. 3-Amino-1-(trans-4-aminocyclohexyl)-2,3-dimethyl-guanidine in the form of a dihydrochloride is obtained. ¹H-NMR: 1.30 – 1.65, m, 4H, CCH₂; 1.78 – 2.15, m, 4H, CCH₂; 2.70 – 3.00, m, 4H, 3H from NCH₃ and 1H from NCH; 3.14, s, 3H, NCH₃; 3.22 – 3.55, m, 1H, NCH; 8.19, b, 3H, NH.


According to the method as described in Example H, but using appropriate starting materials, the compounds of formulae EX_{H2}, EX_{H3} and EX_{H4} in the form of a hydrochloride are obtained:

EX_{H2}

¹H-NMR: (DMSO-d₆/D₂O) 1.20 – 1.50, m, 4H, CCH₂; 1.78 – 2.02, m, 4H, CCH₂; 2.80 – 3.10, m, 1H, NCH; 3.40, s, 3H, NCH₃; 3.80 – 4.05, m, 1H, NCH.

EX_{H3}

(the BOC-protecting group is removed with HCl in MeOH).

EX_{H4}

¹H-NMR: 1.00 – 1.92, m, 17H, 9H from CCH₃ and 8H from CCH₂; 2.56, s, 3H, SCH₃; 3.00 – 3.25, m, 1H, NCH; 3.51, s, 3H, NCH₃; 3.68 – 3.92, m, 1H, NCH (the BOC protecting group is removed with TFA).

Example I**[3-Amino-1-(trans-4-aminocyclohexyl)-3-methyl]-urea****a) [trans-4-(3-Amino-3-methyl-ureido)cyclohexyl-carbamic acid tert-butylester**

A solution of 0.435 g [trans-4-(3-amino-2,3-dimethyl-isothioureido)cyclohexyl]-carbamic acid tert-butyl ester hydrochloride is treated with 0.18 ml of NH₃ (2M in EtOH) and the mixture

obtained is refluxed and stirred at RT. From the mixture obtained solvent is evaporated and [trans-4-(3-amino-3-methyl-ureido)cyclohexyl-carbamic acid tert-butylester is obtained.

¹HNMR: 1.00-1.50, m, 13H, 9H from CCH₃ and 4H from CCH₂; 1.60-1.90, m 4H, CCH₂; 3.08, s, 3H, NCH₃; 3.25-3.80, m, 2H, NCH

5 **b) [3-Amino-1-(trans-4-aminocyclohexyl)-3-methyl]-urea**

A mixture of 0.34 g of [trans-4-(3-amino-3-methyl-ureido)cyclohexyl-carbamic acid tert-butyl ester in 15 ml of MeOH and 2 ml of 2N HCl (in MeOH) is stirred at RT for 4 hours. From the mixture obtained solvent is evaporated, the evaporation residue is treated with H₂O and the pH of the mixture obtained is adjusted with 2N HCl to pH 2. A precipitate formed is filtered
10 off. The filtrate obtained is lyophilized. [3-Amino-1-(trans-4-aminocyclo-hexyl)-3-methyl]-urea in the form of a dihydrochloride is obtained.

Example J

3-Amino-1-(trans-4-aminocyclohexyl)-1,2-dimethyl-guananidine

15 **a) (4-Methylamino-cyclohexyl)carbamic acid benzylester**

A mixture of 3.31 ml of methylamine (33% in absolute EtOH), 4.63 ml of acetic acid and 75 ml of MeOH are added dropwise to a solution of 10 g of (4-oxo-cyclohexyl)carbamic acid benzylester in 27 ml of MeOH. To the mixture obtained a solution of 5 g of sodiumcyano-borhydride in 25 ml of MeOH are added and the mixture obtained is stirred for 72 hours at
20 RT. From the mixture obtained solvent is evaporated, 45 ml of 1N NaOH are added and the mixture obtained is kept at 60° for 40 minutes. The mixture obtained is extracted with CH₂Cl₂, the organic layer obtained is dried and solvent is evaporated. The evaporation residue obtained is treated with 142 ml of 2-methoxy-2-methyl-propane and the suspension obtained is refluxed for 30 minutes. The mixture obtained is filtered. (4-Methylamino-
25 cyclohexyl)carbamic acid benzylester wherein (4-trans-methylamino-cyclohexyl)carbamic acid benzylester is enriched (precipitate) and (4-Methylamino-cyclohexyl)carbamic acid benzylester wherein (4-cis-methylamino-cyclohexyl)carbamic acid benzylester is enriched (filtrate) is obtained. From the sample comprising enriched (4-cis-methylamino-cyclohexyl)carbamic acid benzylester, solvent is evaporated.
30 Each enriched sample obtained is treated with 50 ml of 2M HCl, the suspension obtained is filtered, the pH of the filtrate obtained is adjusted to pH 11.8, and the mixture obtained is extracted with CH₂Cl₂. From the organic phase obtained solvent is evaporated.

2 Products, i.e. (4-methylamino-cyclohexyl)-carbamic acid benzylester

a. wherein (trans-4-methylamino-cyclohexyl)-carbamic acid benzylester is enriched

b. wherein (cis-4-methylamino-cyclohexyl)-carbamic acid benzylester is enriched, are obtained.

b) [4-(1,3-Dimethyl-thioureido)-cyclohexyl]carbamic acid benzylester

A solution of 0.14 g of methylisothiocyanate in 7 ml of CH₂Cl₂ is added dropwise to a solution of 0.5 g of the enriched (trans-4-methylamino-cyclohexyl)-carbamic acid benzylester in 10 ml of CH₂Cl₂, the mixture obtained is stirred for 16 hours at RT and from the mixture obtained solvent is evaporated. [4-(1,3-Dimethyl-thioureido)-cyclohexyl]carbamic acid benzylester is obtained.

c) [4-(1,2,3-Trimethyl-isothioureido)-cyclohexyl]carbamic acid benzylester

0.18 ml of methyl iodide are added to a solution of 0.64 g [4-(1,3-dimethyl-thioureido)-cyclohexyl]carbamic acid benzylester in 30 ml of AcCN. The mixture obtained is refluxed for 2.5 hours and solvent is evaporated. [4-(1,2,3-Trimethyl-isothioureido)-cyclohexyl]-carbamic acid benzylester in the form of a hydroiodide is obtained.

d) [4-(3-Amino-1,2-dimethyl-guanidino)cyclohexyl]carbamic acid benzylester

0.84 g of [4-(1,2,3-trimethyl-isothioureido)-cyclohexyl]carbamic acid benzylester in the form of a hydroiodide are stirred with 10 ml of a strong basic ion exchanger in chloride form. A suspension obtained is filtered and the filtrate obtained is lyophilized. The lyophilisate is treated with 15 ml of EtOH and with 0.08 ml of hydrazine monohydrate. The mixture obtained is refluxed for 2.5 hours and from the mixture obtained solvent is evaporated. [4-(3-Amino-1,2-dimethyl-guanidino)-cyclohexyl]-carbamic acid benzylester in the form of a hydrochloride is obtained.

e) 3-Amino-1-(4-aminocyclohexyl)-1,2-dimethyl-guanidine

A solution of 0.50 g of [4-(3-amino-1,2-dimethyl-guanidino)-cyclohexyl]carbamic acid benzylester in the form of a hydrochloride in 25 ml of CH₂Cl₂ is treated with 0.77 ml of boron tribromide. The mixture obtained is stirred for 30 minutes at RT, the precipitate formed is filtered off and washed with CH₂Cl₂. The precipitate obtained is dissolved in H₂O, treated with 10 ml of strong basic ion exchanger in chloride form and stirred for 2 hours at RT. From the mixture obtained the ion exchanger is filtered off and solvent is evaporated from the filtrate obtained. 3-Amino-1-(4-aminocyclohexyl)-1,2-dimethyl-guanidine in the form of a dihydrochloride is obtained. The ratio trans/cis is about 0.7:0.3 (¹H-NMR data-estimation).

Example K

3-Amino-1-(cis-4-aminocyclohexyl)-1,2,3-trimethyl-guanidine

a) Benzylidene derivative of 3-amino-1-(cis-4-aminocyclohexyl)-1,2-dimethyl-guanidine

A solution of 1.73 g of 3-amino-1-(cis-4-aminocyclohexyl)-1,2-dimethyl-guanidine in the form of a dihydrochloride in 40 ml of H₂O is acidified with 2M HCl and treated with 0.88 ml of benzaldehyde. The mixture obtained is stirred for 3 hours at RT and the excess of benzaldehyde is extracted with diethylether. An aqueous solution of the crude benzylidene derivative of 3-amino-1-(cis-4-aminocyclohexyl)-1,2-dimethyl-guanidine in the form of a hydrochloride is obtained and subjected to chromatography (LiChroprep RP-18^R, Merck, grain size 40-63µm). Fractions containing the desired product are combined. The benzylidene derivative of 3-amino-1-(cis-4-aminocyclohexyl)-1,2-dimethyl-guanidine in the form of a monohydrochloride is obtained. The pH of an aqueous solution of benzylidene derivative of 3-amino-1-(cis-4-aminocyclohexyl)-1,2-dimethyl-guanidine monohydrochloride is adjusted with 2M NaOH to pH 13, the mixture obtained is extracted with CH₂Cl₂, the organic phase obtained is dried and solvent is evaporated. The benzylidene derivative of 3-amino-1-(cis-4-aminocyclohexyl)-1,2-dimethyl-guanidine is obtained.

b) Benzylidene derivative of [cis-4-((hydrazino)methyliminomethyl)-methylaminocyclohexyl]-1-N-formamide

A mixture of 1.08 ml of formic acid and 0.53 ml of acetic anhydride is stirred for 30 minutes at 0° (mixed anhydride formation), and a solution of 0.54 g of benzylidene derivative of 3-amino-1-(cis-4-aminocyclohexyl)-1,2-dimethyl-guanidine in 1.08 ml of formic acid are added dropwise. The mixture obtained is stirred overnight at RT. Solvent is evaporated and the evaporation residue obtained is treated with 40 ml of H₂O. The pH of the solution obtained is adjusted with 2M NaOH to pH 13 and the mixture obtained is extracted with CH₂Cl₂. The organic layer obtained is dried and solvent is evaporated. The benzylidene derivative of [cis-4-((hydrazino)methyliminomethyl)-methylaminocyclohexyl]-1-N-formamide is obtained.

c) Benzylidene derivative of 3-amino-1-(cis-4-aminocyclohexyl)-1,2,3-trimethyl-guanidine

A mixture of 0.59 g of the benzylidene derivative of [cis-4-((hydrazino)methyliminomethyl)-methylaminocyclohexyl]-1-N-formamide in 40 ml of AcCN and 0.29 ml of methyl iodide is refluxed for 4 hours and solvent is evaporated from the mixture obtained. The evaporation residue obtained is treated with 40 ml of H₂O and 10 ml of strong basic ion exchanger in chloride form. The suspension obtained is stirred for 1 hour at RT, the ion exchanger is filtered off and to the filtrate obtained 5 ml of 2M HCl are added. The solution obtained is subjected to steam distillation for 4 hours (complete removal of the formyl group and partial removal of the benzylidene protecting group). In order to fully protect again the hydrazino group, the solution obtained is stirred with 0.38 ml of benzaldehyde for 2 hours at RT and extracted three times with diethylether. The aqueous solution obtained is subjected to

chromatography (LiChroprep RP¹⁸). Fractions containing the desired product are combined, solvent is evaporated and the benzylidene derivative of 3-amino-1-(cis-4-aminocyclohexyl)-1,2,3-trimethyl-guanidine in the form of a hydrochloride is obtained.

d) 3-Amino-1-(cis-4-aminocyclohexyl)-1,2,3-trimethyl-guanidine

- 5 Benzaldehyde is distilled off from a mixture of the benzylidene derivative of 0.32 g of 3-amino-1-(cis-4-aminocyclohexyl)-1,2,3-trimethyl-guanidine in the form of a hydrochloride in 5 ml of HCl and H₂O. From the mixture obtained solvent is evaporated and 3-amino-1-(cis-4-aminocyclohexyl)-1,2,3-trimethyl-guanidine in the form of a dihydrochlorid is obtained.

10 Example L

3-Amino-1-(trans-4-ethylaminocyclohexyl)-3-methyl-guanidine and
3-Amino-1-(trans-4-diethylaminocyclohexyl)-3-methyl-guanidine

a) Benzylidene derivative of 3-amino-1-(trans-4-ethylaminocyclohexyl)-3-methyl-guanidine
and benzylidene derivative of 3-amino-1-(trans-4-diethyl-aminocyclohexyl)-3-methyl-
15 guanidine

- A solution of 0.73 g of the benzylidene derivative of 3-amino-1-(trans-4-aminocyclohexyl)-3-methyl-guanidine and 0.47 ml of N-ethyldiisopropylamine in 40 ml of AcCN is treated with 0.28 ml of ethyl iodide. The mixture obtained is refluxed for 6 hours and solvent is evaporated. A mixture of 3-amino-1-(trans-4-ethylaminocyclohexyl)-3-methyl-guanidine in the
20 form of a dihydrochloride and 3-amino-1-(trans-4-diethylaminocyclohexyl)-3-methyl-guanidine in the form of a dihydrochloride is obtained.

b) Benzylidene derivative of 3-amino-1-(trans-4-ethylaminocyclohexyl)-3-methyl-guanidine
and benzylidene derivative of 3-amino-1-(trans-4-diethyl-aminocyclohexyl)-3-methyl-
25 guanidine







- A solution of 1.29 g of a mixture of 3-amino-1-(trans-4-ethylaminocyclohexyl)-3-methyl-guanidine in the form of a dihydrochloride and 3-amino-1-(trans-4-diethylaminocyclohexyl)-3-methyl-guanidine in the form of a dihydrochloride is treated with 15 ml of a strong basic ion
30 chromatography (LiChroprep RP¹⁸). Two products are eluted and the benzylidene derivative of 3-amino-1-(trans-4-ethylaminocyclohexyl)-3-methyl-guanidine in the form of a hydrochloride and the benzylidene derivative of 3-amino-1-(trans-4-diethylaminocyclohexyl)-3-methyl-guanidine in the form of a hydrochloride are obtained in pure form.

c) 3-Amino-1-(trans-4-diethylaminocyclohexyl)-3-methyl-guanidine

Removal of the benzylidene protecting group from the benzylidene derivative of 3-amino-1-(trans-4-diethylaminocyclohexyl)-3-methyl-guanidine in the form of a hydrochloride is performed according to the method of Example K d).

According to the method described in Example L, but using appropriate starting materials, the compounds L1 to L6 of TABLE 7 below in the form of a hydrochloride are obtained:

TABLE 7

EX	Compound of formula
L1	
L2	
L3	
L4	
L5	
L6	

Example M**3-Amino-1-(trans-4-aminocyclohexyl)-1-methyl-guanidine****a) [(trans-4-Benzylidene-amino)-cyclohexyl]-methyl-cyanamide**

2 ml of benzaldehyde are added to 2.53g of trans-N-methyl-cyclohexan-1,4-diamine in 80 ml
5 of toluene in one single portion. The mixture obtained is refluxed for 4 hours, cooled to RT,
6.9 ml of N-ethyl-diisopropylamin are added and a solution of 2.09 g of cyanogen bromide in
10 ml of toluene are added dropwise. The mixture obtained is stirred overnight at RT. A
precipitate formed is filtered off, solvent from the filtrate obtained is evaporated, the
evaporation residue obtained is treated with H₂O and extracted with diethylether. The
organic layer obtained is dried and solvent is evaporated. [(trans-4-Benzylidene-amino)-
cyclohexyl]-methyl-cyanamide is obtained.

b) 1-(trans-4-Aminocyclohexyl)-1-methyl-thiourea

20 ml of EtOH saturated with 3 g of H₂S are added to a solution of 4.23 g of [(trans-4-
benzylidene-amino)-cyclohexyl]-methyl-cyanamide and 4.1 ml of triethylamine in 60 ml of
15 EtOH. The mixture obtained is heated in an autoclave for 4 hours at 120°. From the mixture
obtained solvent and excess of H₂S are removed by distillation. The distillation residue
obtained is treated with 20 ml of 2M HCl and 10 ml of H₂O and 50 ml of a strong basic ion
changer in chloride form are added. The suspension obtained is stirred for 1 hour, the ion
exchanger is filtrated off and the acidic filtrate obtained is subjected to chromatography
20 (LiChroprep RP-18^R, Merck, grain size 40-63µm). 1-(trans-4-Aminocyclohexyl)-1-methyl-
thiourea in the form of a hydrochloride is obtained.

c) 1-(trans-4-Aminocyclohexyl)-1,2-dimethyl-isothiurea

A mixture of 0.6 g of 1-(trans-4-aminocyclohexyl)-1-methyl-thiourea in the form of a
hydrochloride in 30 ml of MeOH and 0.22 ml of methyl iodide is refluxed for 2 hours, solvent
25 is evaporated and 1-(trans-4-aminocyclohexyl)-1,2-dimethyl-isothiurea in the form of a
hydrochloride and a hydroiodide is obtained.

d) 3-Amino-1-(trans-4-aminocyclohexyl)-1-methyl-guanidine

A solution of 0.50 g of 1-(trans-4-aminocyclohexyl)-1,2-dimethyl-isothiurea in the form of
hydrochloride and a hydroiodide in 40 ml of EtOH is treated with 0.15 ml of hydrazine
30 monohydrate and the mixture obtained is refluxed for 2 hours. Solvent from the mixture
obtained is evaporated, the evaporation residue obtained is treated with 20 ml of H₂O and to
the mixture obtained 10 ml of a strong basic ion changer in chloride form are added. The
suspension obtained is stirred for 1 hour, the ion exchanger is filtered off, from the filtrate

obtained solvent is evaporated and 3-amino-1-(trans-4-aminocyclohexyl)-1-methyl-guanidine in the form of a dihydrochloride is obtained.

Example N

5 3-Amino-1-(trans-4-aminocyclohexyl)-1,3-dimethyl-guanidine

a) Benzylidene derivative of 3-amino-1-(trans-4-aminocyclohexyl)-1-methyl-guanidine

A solution of 0.79 g of 3-amino-1-(trans-4-aminocyclohexyl)-1-methyl-guanidine in the form of a dihydrochloride in 20 ml of H₂O is treated with 0.46 ml of benzaldehyde and the mixture obtained is stirred overnight. The mixture obtained is extracted with diethylether and the
10 aqueous layer obtained is subjected to chromatography. The product is eluted and desired fractions are combined, the pH of the solution obtained is adjusted with 2M NaOH to pH 13 and the mixture obtained is extracted with CH₂Cl₂. The organic layer obtained is dried and solvent is evaporated. The benzylidene derivative of 3-amino-1-(trans-4-aminocyclohexyl)-1-methyl-guanidine is obtained.

15 b) Benzylidene derivative of [trans-4-((hydrazino)iminomethyl)methylaminocyclo-hexyl]-acetamide

0.06 ml of acetylchloride are added to a suspension of 0.22 g of the benzylidene derivative of 3-amino-1-(trans-4-aminocyclohexyl)-1-methyl-guanidine and 0.08 g of K₂CO₃ in 15 ml of CH₂Cl₂, the mixture obtained is stirred for 4 hours at RT and solvent is evaporated. The
20 evaporation residue obtained is treated with 20 ml of H₂O and the pH of the solution obtained is adjusted with 2M NaOH to pH 13. The mixture obtained is extracted with CH₂Cl₂, dried and solvent is evaporated. The benzylidene derivative of [trans-4-((hydrazino)-iminomethyl)methylaminocyclohexyl]-acetamide is obtained.

25 c) Benzylidene derivative of [trans-4-((1-methylhydrazino)iminomethyl)methylamino-cyclohexyl]-acetamide

A mixture of 0.23 g of the benzylidene derivative of [trans-4-((hydrazino)iminomethyl)methylamino-cyclohexyl]-acetamide, 20 ml of AcCN and 0.1 ml of methyl iodide is refluxed for 4 hours. From the mixture obtained solvent is evaporated and the benzylidene derivative of [trans-4-((1-methylhydrazino)iminomethyl)methylaminocyclohexyl]-acetamide is obtained in
30 the form of a hydroiodide.

d) 3-Amino-1-(trans-4-aminocyclohexyl)-1,3-dimethyl-guanidine

To 0.30 g of the benzylidene derivative of [trans-4-((1-methylhydrazino)iminomethyl)methylaminocyclohexyl]-acetamide in the form of a hydroiodide in 20 ml of H₂O, a strong basic ion exchanger in chloride form is added and the suspension obtained is stirred for 1 hour. The
35 ion exchanger is filtrated off and, 5 ml of 2M HCl are added to the filtrate obtained.

- 43 -

The mixture obtained is subjected to steam distillation (both protecting groups, i.e. the benzylidene and the acetyl group are removed), from the mixture obtained solvent is evaporated and 3-amino-1-(trans-4-aminocyclohexyl)-1,3-dimethyl-guanidine in the form of a dihydrochloride is obtained.

¹H-NMR-Spectra
(200 MHz, in DMSO-d₆ unless given otherwise)

2	1.40 – 2.12, m, 8H, CCH ₂ ; 3.10 – 3.30, m, 1H, NCH; 3.35, s, 3H, NCH ₃ ; 3.55 and 4.54, AB-quartet, J=18 Hz, 2H, SCH ₂ ; 3.75 – 3.95, m, 1H, NCH; 5.15, d, J=5 Hz, 1H, β-lactam; 5.77, d, J=55 Hz, 2H, CH ₂ F; 5.78, dd, J=5 Hz and 8 Hz, 1H, β-lactam; 8.12, s, 1H, CH=N; 9.86, d, J=8 Hz, 1H, NH
5	
3	1.06, t, J=5 Hz, 3H, CH ₃ ; 1.32 – 1.70, m, 4H, CCH ₂ ; 1.75 – 2.12, m, 4H, CCH ₂ ; 2.88 – 3.10, m, 1H, NCH; 3.48 – 3.72, m, 2H, 1H from SCH ₂ and 1H from NCH; 3.98, m, 2H, NCH ₂ ; 4.24, part of the AB-quartet, J=18 Hz, 1H, SCH ₂ ; 5.14, d, J=5 Hz, 1H, β-lactam; 5.79, d, J=55 Hz, 2H, CH ₂ F; 5.77, dd, J=5 Hz and 8 Hz, 1H, β-lactam; 8.12, s, 1H, CH=N; 9.84, d, J=8 Hz, 1H, NH
10	
4	(in D ₂ O) 1.28 – 1.65, m, 4H, CCH ₂ ; 1.80 – 2.10, m, 4H, CCH ₂ ; 2.82 – 3.08, m, 1H, NCH; 3.32 – 3.60, m, 2H, 1H from NCH ₂ and 1H from SCH ₂ ; 4.14, part of the AB-quartet, J=18 Hz, 1H, SCH ₂ ; 5.09, d, J=5 Hz, 1H, β-lactam; 5.69, d, 1H, β-lactam; 6.65, s, 1H, CH thiazol; 8.21, s, 1H, CH=N
15	
5	1.35 – 1.68, m, 4H, CCH ₂ ; 1.78 – 2.12, m, 4H, CCH ₂ ; 2.82 – 3.06, m, 1H, NCH; 3.35, s, 3H, NCH ₃ ; 3.50 – 3.80, m, 2H, 1H from NCH and 1H from SCH ₂ ; 3.90, s, 3H, OCH ₃ ; 4.58, part of the AB-quartet, J=18 Hz, 1H, SCH ₂ ; 5.28, d, J=5 Hz, 1H, β-lactam; 5.90, dd, J=5 Hz and 8 Hz, 1H, β-lactam; 6.85, s, 1H, CH thiazol; 8.08, s, 1H, CH=N; 9.79, d, J=8 Hz, 1H, NH
20	
6	1.30 – 1.70, m, 4H, CCH ₂ ; 1.82 – 2.08, m, 4H, CCH ₂ ; 2.88 – 3.10, m, 1H, NCH; 3.40 – 3.68, m, 2H, 1H from NCH and 1H from SCH ₂ ; 4.42 – 4.78, m, 3H, 2H from NCH ₂ and 1H from SCH ₂ ; 4.92 – 5.35, m, 3H, 1H from β-lactam and 2H from CH ₂ =C; 5.52 – 6.04, m, 4H, 1H from β-lactam, 1H from C–CH=C and 2H from CH ₂ F; 8.08, s, 1H, CH=N; 9.84, d, J=8 Hz, 1H, NH
25	
7	1.15 – 1.50, m, 4H, CCH ₂ ; 1.60 – 1.82, m, 2H, CCH ₂ ; 1.88 – 2.20, m, 2H, CCH ₂ ; 3.00 – 3.30, m, 1H, NCH; 3.45 – 3.75, m, 2H, 1H from NCH and 1H from SCH ₂ ; 4.52, part of the AB-quartet, J=18 Hz, 1H, SCH ₂ ; 5.28, d, J=5 Hz, 1H, β-lactam; 5.78, d, J=55 Hz, 2H, CH ₂ F; 5.92, dd, J=5 Hz and 8 Hz, 1H, β-lactam; 8.32, s, 1H, CH=N; 9.82, d, J=8 Hz, 1H, NH
30	
8	1.28 – 1.62, m, 4H, NCH ₂ ; 1.78 – 2.12, m, 4H, NCH ₂ ; 2.88 – 3.12, m, 1H, NCH; 3.40 – 3.70, m, 2H, 1H from NCH and 1H from SCH ₂ ; 4.48, part of the AB-quartet, J=18 Hz, 1H, SCH ₂ ; 5.27, d, J=5 Hz, 1H, β-lactam; 5.77, d, J=55 Hz, 2H, CH ₂ F; 5.90, dd, J=5 Hz and 8 Hz, 1H, β-lactam; 8.28, s, 1H, CH=N; 10.82, d, J=8 Hz, 1H, NH
35	
9	1.20 – 1.65, m, 4H, CCH ₂ ; 1.90 – 2.12, m, 4H, CCH ₂ ; 2.75, b, 6H, NCH ₃ ; 3.00 – 3.60, m, 3H, 2 from NCH and 1H from SCH ₂ ; 4.32, part of the AB-quartet, J=18 Hz, 1H, SCH ₂ ; 5.22, d, J=5 Hz, 1H, β-lactam; 5.79, d, J=55 Hz, 2H, CH ₂ F; 5.80, dd, J=5 Hz and 8 Hz, 1H, β-lactam; 8.22, s, 1H, CH=N; 9.78, d, J=8 Hz, 1H, NH
40	
10	1.30 – 1.70, m, 4H, CCH ₂ ; 1.92 – 2.32, m, 4H, CCH ₂ ; 3.05, b, 9H, NCH ₃ ; 3.20 – 3.68, m, 3H, 2H from NCH and 1H from SCH ₂ ; 4.48, part of the AB-quartet, J=18 Hz, 1H, SCH ₂ ; 5.28, d, J=5 Hz, 1H, β-lactam; 5.78, d, J=55 Hz, 2H, CH ₂ F; 5.94, dd, J=5 Hz and 8 Hz, 1H, β-lactam; 8.30, s, 1H, CH=N; 9.84, d, J=8 Hz, 1H, NH
45	
11	1.15 – 1.58, m, 4H, CCH ₂ ; 1.65 – 2.30, m, 4H, CCH ₂ ; 2.92, s, 3H, NCH ₃ ; 3.08 – 3.75, m, 3H, 2H from NCH and 1H from SCH ₂ ; 4.48, part of the AB-quartet, J=18 Hz, 1H, SCH ₂ ; 5.32, d, J=5 Hz, 1H, β-lactam; 5.77, d, J=55 Hz, 2H, CH ₂ F; 5.95, dd, J=5 Hz and 8 Hz, 1H, β-lactam; 8.52, s, 1H, CH=N; 9.82, d, J=8 Hz, 1H, NH
50	
12	1.40 – 1.75, m, 4H, CCH ₂ ; 1.92 – 2.32, m, 4H, CCH ₂ ; 3.04, b, 9H, NCH ₃ ; 3.25 – 3.80, m, 6H, 3H from NCH ₃ and 2H from NCH and 1H from SCH ₂ ; 4.58, part of the AB-quartet, J=18 Hz, 1H, SCH ₂ ; 5.27, d, J=5 Hz, 1H, β-lactam; 5.78, d, J=55 Hz, 2H,


- CH₂F; 5.96, dd, J=5 Hz and 8 Hz, 1H, β -lactam; 8.07, s, 1H, CH=N; 9.86, d, J=8 Hz, 1H, NH
- 13 1.10 – 1.45, m, 4H, CCH₂; 1.55 – 1.88, m, 4H, CCH₂; 2.65 – 2.95, m, 1H, NCH; 3.28, s, 3H, NCH₃; 3.32 – 3.60, m, 2H, 1H from NH and 1H from SCH₂; 4.50, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 5.26, d, J=5 Hz, 1H, β -lactam; 5.77, d, J=55 Hz, 2H, CH₂F; 5.96, dd, J=5 Hz and 8 Hz, 1H, β -lactam; 6.60, d, J=9 Hz, 2H, aromatic-H; 7.42, d, J=9 Hz, 2H, aromatic-H; 8.07, s, 1H, CH=N; 9.75, d, J=8 Hz, 1H, NH
- 5 14 1.30 – 1.58, m, 2H, CCH₂; 1.62 – 1.88, m, 4H, CCH₂; 2.00 – 2.22, m, 2H, CCH₂; 2.54, s, 3H, NCH₃; 2.72 – 3.10, m, 7H, 6H from NCH₃ and 1H from NCH; 3.48-3.72, m, 2H, 1H from NCH and 1H from SCH₂; 4.10, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 5.28, d, J=5 Hz, 1H, β -lactam; 5.77, d, J=55 Hz, 2H, CH₂F; 5.94, dd, J=5 Hz and 8 Hz, 1H, β -lactam; 8.47, s, 1H, CH=N; 9.84, d, J=8 Hz, 1H, NH
- 10 15 1.30 – 1.70, m, 4H, CCH₂; 1.72 – 2.10, m, 4H, CCH₂; 2.70 – 3.10, m, 4H, 3H from NCH₃ and 1H from NCH; 3.35 – 3.70, m, 2H, 1H from NCH and 1H from SCH₂; 3.50, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 5.28, d, J=5 Hz, 1H, β -lactam; 5.78, dd, J=55 Hz, 2H, CH₂F; 5.94, dd, J=5 Hz and 8 Hz, 1H, β -lactam; 8.55, s, 1H, CH=N; 9.85, d, J=8 Hz, 1H, NH
- 15 16 1.32 – 1.70, m, 4H, CCH₂; 1.80 – 2.20, m, 4H, CCH₂; 2.70, b, 6H, NCH₃; 2.88, d, 3H, NCH₃; 3.00 – 3.20, m, 1H, NCH; 3.38 – 3.70, m, 2H, 1H from NCH and 1H from SCH₂; 4.52, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 5.29, d, J=5 Hz, 1H, β -lactam; 5.78, d, J=55 Hz, 2H, CH₂F; 5.94, dd, J=5 Hz and 8 Hz, 1H, β -lactam; 8.28, b, 2H, NH₂; 8.63, s, 1H, CH=N; 9.84, d, J=8 Hz, 1H, NH
- 20 17 1.40 – 1.70, m, 4H, CCH₂; 1.88 – 2.30, m, 4H, CCH₂; 2.88, d, 3H, NCH₃; 3.08, b, 9H, NCH₃; 3.20 – 3.80, m, 3H, 2H from NCH and 1H from SCH₂; 4.51, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 5.29, d, J=5 Hz, 1H, β -lactam; 5.78, d, J=55 Hz, 2H, CH₂F; 5.95, dd J=5 Hz and 8 Hz, 1H, β -lactam; 8.30, b, 2H, NH₂; 8.68, s, 1H, CH=N; 9.84, d, J=8 Hz, 1H, NH
- 25 18 1.10 – 2.22, m, 8H, CCH₂; 2.90, d, 3H, NCH₃; 3.08 – 3.32, m, 1H, NCH; 3.40 – 3.80, m, 2H, 1H from NCH and 1H from SCH₂; 3.54, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 5.30, d, J=5 Hz, 1H, β -lactam; 5.77, d, J=55 Hz, 2H, CH₂F; 5.96, dd, J=5 Hz and 8 Hz, 1H, β -lactam; 8.52, s, 1H, CH=N; 9.86, d, J=8 Hz, 1H, NH
- 30 19 1.30 – 1.75, m, 8H, CCH₂; 1.80 – 2.20, m, 8H, CCH₂; 2.80 – 3.20, m, 2H, NCH; 3.28, s, 3H, NCH₃; 3.40 – 3.75, m, 3H, 2H from NCH and 1H from SCH₂; 4.20, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 5.15, d, J=5 Hz, 1H, β -lactam; 5.76, dd, J=5 Hz and 8 Hz, 1H, β -lactam; 5.79, d, J=55 Hz, 2H, CH₂F; 8.09, s, 1H, CH=N; 9.84, d, J=8 Hz, 1H, NH
- 35 20 1.02 – 2.20, m, 8H, CCH₂; 2.90 – 3.18, m, 1H, NCH; 3.32, s, 3H, NCH₃; 3.42 – 3.78, m, 2H, 1H from NCH and 1H from SCH₂; 3.55, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 5.28, d, J=5 Hz, 1H, β -lactam; 5.78, d, J=55 Hz, 2H, CH₂F; 5.94, dd, J=5 Hz and 8 Hz, 1H, β -lactam; 8.12, s, 1H, CH=N; 9.82, d, J=8 Hz, 1H, NH
- 40 21 1.10 – 2.22, m, 8H, CCH₂; 3.00 – 3.18, m, 1H, NCH; 3.35, b, 3H, NCH₃; 3.45 – 3.82, m, 1.5H, 1H from SCH₂ and 0.5H from NCH; 4.10 – 4.30, m, 0.5H, NCH; 3.54, part of the AB-quartet, J=18 Hz, 0.5H, SCH₂; 3.62, part of the AB-quartet, J=18 Hz, 0.5H, SCH₂; 5.12 – 5.22, m, 1H, β -lactam; 5.70 – 5.85, m, 1H, β -lactam; 5.78, d, J=5 Hz, 2H, CH₂F; 8.10, b, 1H, CH=N; 9.77, d, J=8 Hz, 1H, NH
- 45 22 1.08 – 1.62, m, 4H, CCH₂; 1.70 – 2.25, m, 4H, CCH₂; 2.90 – 3.20, m, 1H, NCH; 3.32, b, 3H, NCH₃; 3.42 – 3.82, m, 2H, 1H from NCH and 1H from SCH₂; 4.45 – 4.70, m, 1H, SCH₂; 5.10 – 5.28, m, 1H, β -lactam; 5.65 – 5.90, m, 1H, β -lactam; 5.78, d, J=55 Hz, 2H, CH₂F; 8.10, b, 1H, CH=N; 9.85, d, J=8 Hz, 1H, NH
- 50 23 1.30 – 2.00, m, 7H, CCH₂; 2.10 – 2.30, m, 1H, CCH₂; 3.25 – 3.62, m, 5H, 3H from NCH₃, 1H from NCH and 1H from SCH₂; 3.98 – 4.18, m, 1H, NCH; 4.53, part of the

- AB-quartet, J=18 Hz, 1H, SCH₂; 5.18, d, J=5 Hz, 1H, β-lactam; 5.78, dd, J=5 Hz and 8 Hz, 1H, β-lactam; 5.79, d, J=55 Hz, 2H, CH₂F; 8.11, s, 1H, CH=N; 9.75, d, J=8 Hz, 1H, NH
- 24 1.30 – 1.70, m, 10H, 4H from CCH₂ and 6H from CCH₃; 1.82 – 2.12, m, 4H, CCH₂;
5 2.88 – 3.12, m, 1H, NCH; 3.29, s, 3H, NCH₃; 3.42 – 3.70, m, 2H, 1H from NCH and 1H from SCH₂; 4.48, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 5.32, d, J=5 Hz, 1H, β-lactam; 5.98, dd, J=5 Hz and 8 Hz, 1H, β-lactam; 7.06, s, 1H, CH thiazol; 8.11, s, 1H, CH=N; 9.68, d, J=8 Hz, 1H, NH
- 25 1.22 – 1.70, m, 4H, CCH₂; 1.82 – 2.18, m, 4H, CCH₂; 2.88 – 3.18, m, 1H, NCH; 3.45 –
10 3.80, m, 4H, 3H from NCH₃ and 1H from SCH₂; 3.96 – 4.28, m, 1H, NCH; 4.48, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 5.25, d, J=5 Hz, 1H, β-lactam; 5.78, d, J=55 Hz, 2H, CH₂F; 5.96, dd, J=5 Hz and 8 Hz, 1H, β-lactam; 8.02, s, 1H, CH=N; 9.86, d, J=8 Hz, 1H, NH
- 26 1.30 – 1.60, m, 4H, CCH₂; 1.70 – 2.05, m, 4H, CCH₂; 2.80 – 3.05, m, 1H, NCH; 3.18,
15 s, 3H, NCH₃; 3.38 – 3.68, m, 2H, 1H from NCH and 1H from SCH₂; 4.48, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 5.22, d, J=5 Hz, 1H, β-lactam; 5.76, d, J=55 Hz, 2H, CH₂F; 5.92, dd, J=5 Hz and 8 Hz, 1H, β-lactam; 7.85, s, 1H, CH=N; 9.82, d, J=8 Hz, 1H, NH
- 27 1.10 – 1.65, m, 4H, CCH₂; 1.72 – 2.25, m, 4H, CCH₂; 2.88 – 3.18, m, 1H, NCH; 3.32,
20 s, 3H, NCH₃; 3.42 – 3.80, m, 2H, 1H from NCH and 1H from SCH₂; 4.54, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 5.17, d, J=5 Hz, 1H, β-lactam; 5.77, dd, J=5 Hz and 8 Hz, 1H, β-lactam; 5.78, d, J=55 Hz, 2H, CH₂F; 8.10, s, 1H, CH=N; 9.85, d, J=5 Hz, 1H, NH
- 28 1.28 – 1.68, m, 4H, CCH₂; 1.88 – 2.15, m, 4H, CCH₂; 2.72 – 3.08, m, 4H, 3H from
25 NCH₃ and 1H from NCH; 3.28, s, 3H, NCH₃; 3.40 – 3.72, m, 2H, 1H from NCH and 1H from SCH₂; 4.25, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 5.27, d, J=5 Hz, 1H, β-lactam; 5.78, d, J=55 Hz, 2H, CH₂F; 5.94, dd, J=5 Hz and 8 Hz, 1H, β-lactam; 8.06, s, 1H, CH=N; 9.85, d, J=8 Hz, 1H, NH
- 29 (500 MHz, CDCl₃/CH₃OD)
30 0.82 – 0.88, m, 2H, CCH₂; 1.32 – 2.14, m, 10H, CCH₂; 2.68 – 2.82, m, 2H, NCH; 3.52 –
3.72, m, 2H, 1H from SCH₂ and 1H from NCH; 4.12, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 5.15, d, J=5 Hz, 1H, β-lactam; 5.78, d, J=55 Hz, 2H, CH₂F; 5.96, d, J=5 Hz, 1H, β-lactam; 8.65, s, 1H, CH=N
- 30 1.38 – 2.15, m, 8H, CCH₂; 2.78 – 3.10, m, 7H, 6H from NCH₃ and 1H from NCH; 3.35
35 – 3.70, m, 2H, 1H from SCH₂ and 1H from NCH; 4.11, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 5.28, d, J=5 Hz, 1H, β-lactam; 5.77, d, J=55 Hz, 2H, CH₂F; 5.94, dd, J=5 Hz and 8 Hz, 1H, β-lactam; 8.47, s, 1H, CH=N; 9.85, d, J=8 Hz, 1H, NH
- 31 1.28 – 2.10, m, 8H, CCH₂; 2.80 – 3.10, m, 7H, 6H from NCH₃ and 1H from NCH; 3.40
40 – 3.70, m, 2H, 1H from SCH₂ and 1H from NCH; 4.12, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 5.29, d, J=5 Hz, 1H, β-lactam; 5.78, d, J=55 Hz, 2H, CH₂F; 5.94, dd, J=5 Hz and 8 Hz, 1H, β-lactam; 8.47, s, 1H, CH=N; 9.85, d, J=8 Hz, 1H, NH
- 32 (D₂O) 1.65 – 2.15, m, 8H, CCH₂; 2.75 – 3.05, m, 6H, NCH₃; 3.22, s, 3H, NCH₃; 3.40 –
45 3.70, m, 3H, 2H from NCH and 1H from SCH₂; 3.90, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 5.22, d, J=5 Hz, 1H, β-lactam; 5.76, d, J=55 Hz, 2H, CH₂F; 5.80, d, J=5 Hz, 1H, β-lactam; 7.90, s, 1H, CH=N
- 33 (D₂O) 1.25 – 1.60, m, 4H, CCH₂; 1.90 – 2.25, m, 4H, CCH₂; 3.00 – 3.28, m, 4H, 3H
50 from NCH₃ and 1H from NCH; 3.35 – 3.68, m, 4H, 2H from NCH₂ and 1H from SCH₂ and 1H from NCH; 3.95, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 5.22, d, J=5 Hz, 1H, β-lactam; 5.30 – 5.50, m, 2H, CH₂=C; 5.74, d, J=55 Hz, 2H, CH₂F; 5.65 – 5.88, m, 2H, 1H from CH=C and 1H from β-lactam; 7.89, s, 1H, CH=N


- 34 (D₂O) 1.30 – 1.80, m, 4H, CCH₂; 1.98 – 2.20, m, 4H, CCH₂; 3.20, s, 3H, NCH₃; 3.30 – 4.05, m, 8H, 4H from NCH₂ and 2H from NCH and 2H from SCH₂; 5.21, d, J=5 Hz, 1H, β-lactam; 5.40 – 5.98, m, 9H, 4H from CH₂=C and 2H from CH=C and 2H from CH₂F and 1H from β-lactam; 7.89, s, 1H, CH=N
- 5 35 (D₂O) 1.10 – 1.65, m, 16H, 4H from CCH₂ and 12H from CH₃; 1.90 – 2.20, m, 4H, CCH₂; 3.05 – 3.30, m, 4H, 3H from NCH₃ and 1H from NCH; 3.35 – 3.60, m, 3H, 2H from NCH and 1H from SCH₂; 3.65 – 4.05, m, 2H, 1H from SCH₂ and 1H from NCH; 5.22, d, J=5 Hz, 1H, β-lactam; 5.75, d, J=55 Hz, 2H, CH₂F; 5.78, d, J=5 Hz, 1H, β-lactam; 7.90, s, 1H, CH=N
- 10 36 (D₂O) 1.20, d, J=6 Hz, 6H, CH₃; 1.30 – 1.65, m, 4H, CCH₂; 1.90 – 2.20, m, 4H, CCH₂; 3.05 – 3.30, m, 4H, 3H from NCH₃ and 1H from NCH; 3.35 – 3.68, m, 3H, 1H from SCH₂ and 2H from NCH; 3.95, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 5.21, d, J=5 Hz, 1H, β-lactam; 5.74, d, J=5 Hz, 1H, β-lactam; 5.75, d, J=55 Hz, 2H, CH₂F; 7.89, s, 1H, CH=N
- 15 37 (D₂O) 1.16, t, J=7 Hz, 3H, CH₃; 1.30 – 1.60, m, 4H, CCH₂; 1.92 – 2.25, m, 4H, CCH₂; 2.90 – 3.30, m, 6H, 3H from NCH₃ and 2H from NCH₂ and 1H from NCH; 3.32 – 3.65, m, 2H, 1H from SCH₂ and 1H from NCH; 3.95, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 5.21, d, J=5 Hz, 1H, β-lactam; 5.73, d, J=55 Hz, 2H, CH₂F; 5.74, d, J=5 Hz, 1H, β-lactam; 7.89, s, 1H, CH=N
- 20 38 (D₂O) 1.21, t, J=7 Hz, 6H, CH₃; 1.35 – 1.75, m, 4H, CCH₂; 1.90 – 2.20, m, 4H, CCH₂; 2.92 – 3.70, m, 10H, 3H from NCH₃ and 4H from NCH₂ and 2H from NCH and 1H from SCH₂; 3.93, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 5.21, d, J=5 Hz, 1H, β-lactam; 5.72, d, J=5 Hz, 1H, β-lactam; 5.74, d, J=55 Hz, 2H, CH₂F; 7.89, s, 1H, CH=N
- 25 39 (D₂O) 0.86, t, J=7 Hz, 3H, CH₃; 1.30 – 1.70, m, 6H, CCH₂; 1.90 – 2.28, m, 4H, CCH₂; 2.80 – 3.28, m, 6H, 3H from NCH₃ and 2H from NCH₂ and 1H from NCH; 3.32 – 3.62, m, 2H, 1H from NCH and 1H from SCH₂; 3.93, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 5.21, d, J=5 Hz, 1H, β-lactam; 5.73, d, J=55 Hz, 2H, CH₂F; 5.74, d, J=5 Hz, 1H, β-lactam; 7.89, s, 1H, CH=N
- 30 40 (D₂O) 0.86, t, J=7 Hz, 6H, CH₃; 1.30 – 1.78, m, 8H, CCH₂; 1.92 – 2.22, m, 4H, CCH₂; 2.82 – 3.65, m, 10H, 3H from NCH₃ and 4H from NCH₂ and 2H from NCH and 1H from SCH₂; 3.96, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 5.21, d, J=5 Hz, 1H, β-lactam; 5.73, d, J=55 Hz, 2H, CH₂F; 5.74, d, J=5 Hz, 1H, β-lactam; 7.92, s, 1H, CH=N
- 35 41 (D₂O) 1.28 – 1.65, m, 4H, CCH₂; 1.95 – 2.25, m, 4H, CCH₂; 2.60, s, 3H, NCH₃; 2.90 – 3.15, m, 1H, NCH; 3.20, s, 3H, NCH₃; 3.32 – 3.65, m, 2H, 1H from NCH and 1H from SCH₂; 3.95, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 5.21, d, J=5 Hz, 1H, β-lactam; 5.73, d, J=55 Hz, 2H, CH₂F; 5.74, d, J=5 Hz, 1H, β-lactam; 7.89, s, 1H, CH=N
- 40 42 (D₂O) 1.32 – 2.25, m, 8H, CCH₂; 2.75 – 3.28, m, 4H, 3H from NCH₃ and 1H from NCH; 3.40 – 3.85, m, 2H, 1H from NCH and 1H from SCH₂; 3.95, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 5.22, d, J=5 Hz, 1H, β-lactam; 5.75, d, J=55 Hz, 2H, CH₂F; 5.76, d, J=5 Hz, 1H, β-lactam; 8.18, s, 1H, CH=N
- 45 43 (D₂O) 1.28 – 2.20, m, 8H, CCH₂; 2.81, s, 3H, NCH₃; 3.05 – 3.30, m, 4H, 3H from NCH₃ and 1H from NCH; 3.40 – 3.70, m, 2H, 1H from NCH and 1H from SCH₂; 3.95, part of the AB-quartet, J=18 Hz, 1H, SCH₂; 5.22, d, J=5 Hz, 1H, β-lactam; 5.75, d, J=55 Hz, 2H, CH₂F; 5.79, d, J=5 Hz, 1H, β-lactam; 7.90, s, 1H, CH=N

Patent claims

1. A compound of formula



5 or of formula



wherein


W is CH or N,

R₁ is hydroxy, (C₁₋₈)alkoxy, halo(C₁₋₈)alkoxy, hydroxycarbonyl(C₁₋₈)alkoxy or (C₁₋₈)alkoxycarbonyl(C₁₋₈)alkoxy,

R₂ is hydrogen or an ester moiety,

R₃ is hydrogen, (C₁₋₈)alkyl, (C₂₋₈)alkenyl or (C₃₋₈)cycloalkyl,

R₄ is hydrogen or (C₁₋₈)alkyl,



is cyclohexyl or phenyl,

- 15 R₅ and R₆ independently of each other are hydrogen; (C₁₋₈)alkyl; (C₂₋₈)alkenyl; (C₆₋₁₈)arylcarbonyl; (C₁₋₈)alkylcarbonyl; (C₆₋₁₈)aryloxy(C₁₋₄)alkylcarbonyl; (C₁₋₈)alkylcarbonyl-(C₆₋₁₈)arylcarbonyl; heterocyclyl(C₁₋₈)alkylcarbonyl, wherein heterocyclyl comprises 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O or S; (C₁₋₈)alkylsulfonyl or (C₆₋₁₈)arylsulfonyl,
- 20 X is NH, O, S or N-R₈, wherein R₈ is (C₁₋₈)alkyl or (C₃₋₈)cycloalkyl,
Y is O or S, and
n and m independently of each other are 0 or 1.

2. A compound of formula IA or IB wherein


W is CH or N,

R₁ is hydroxy, methoxy, fluoromethoxy or (hydroxycarbonyl)(dimethyl)methoxy,

R₂ is hydrogen,

5 R₃ is hydrogen; (C₁₋₄)alkyl, e.g. methyl or ethyl; allyl or cyclopropyl,

R₄ is hydrogen or (C₁₋₄)alkyl, e.g. methyl,



is cyclohexyl, e.g. and the $-(CH_2)_m-NR_5R_6$ group is in the ortho, meta or para position,

R₅ and R₆ independently of each other are hydrogen; (C₁₋₃)alkyl; allyl;

10 (C₁₋₄)alkylcarbonyl; phenylcarbonyl, wherein phenyl is optionally substituted by (C₁₋₄)alkylcarbonyloxy; phenoxymethylcarbonyl; phenylsulfonyl, wherein phenyl is substituted by amino or (C₁₋₄)alkylcarbonylamino, or heterocyclyl comprising 5 ring members and 1 heteroatom selected from N, O or S,

X is NH, NCH₃, NCH(CH₃)₂, O, S or (C₃₋₈)cycloalkyl substituted by amino,

15 n is 0, m is 0,

Y is S and

R₈ is C₁₋₄)alkyl.


3. A compound of formula IA wherein

20 W is N or CH,

R₁ is hydroxy or fluoromethoxy,

R₂, R₄, R₅ and R₆ are hydrogen,

R₃ is C₁₋₄)alkyl,



is cyclohexyl,

25 X is NH,

n is 1 and m is 1.

4. A compound of formula IA wherein


W is N,

30 R₁ is fluoromethoxy,

- 50 -

R_2 , R_4 , R_5 and R_6 are hydrogen,

R_3 is C_{1-4} alkyl,



is phenyl,

X is NH,

n is 1 and m is 0.

5

5. A compound of formula IA wherein


W is CH or N,

R_1 is hydroxy or fluoromethoxy,

10

R_2 , R_4 , R_5 and R_6 are hydrogen,

R_3 is C_{1-4} alkyl,




is phenyl,

X is NH,

n is 1 and m is 1.

15

6. A compound of formula



7. A compound of any one of claims 1 to 6 in the form of a salt.

20

8. A pharmaceutical composition comprising a compound according to any one of claims 1 to 7 in association with at least one pharmaceutical excipient.

9. Use of a compound according to any one of claims 1 to 7 as a pharmaceutical.

25

10. A method of treatment of microbial diseases which comprises administering to a subject in need of such treatment an effective amount of a compound according to any one of claims 1 to 7.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/07603

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D501/00 A61K31/546 A61P31/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 35692 A (BIOCHEMIE GMBH ;ASCHER GERD (AT); LUDESCHER JOHANNES (AT)) 14 November 1996 (1996-11-14) The whole document, especially examples 21,22,89	1-10
A	GB 1 460 377 A (SHIONOGI & CO) 6 January 1977 (1977-01-06) abstract page 12 -page 13 page 23 -page 24 examples 16-21 claims 1,8,11,33,58,60,90,96	1-10

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

23 October 2003

Date of mailing of the international search report

05/11/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Papathoma, S

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 03/07603

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 10 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/07603

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9635692	A	14-11-1996	AT 402820 B	25-09-1997
			AT 402821 B	25-09-1997
			AT 403283 B	29-12-1997
			AT 403284 B	29-12-1997
			AT 79495 A	15-01-1997
			AT 233268 T	15-03-2003
			AU 712814 B2	18-11-1999
			AU 5818496 A	29-11-1996
			BR 9608517 A	08-06-1999
			CA 2219656 A1	14-11-1996
			CN 1186494 A	01-07-1998
			CZ 9703529 A3	18-02-1998
			DE 69626389 D1	03-04-2003
			DE 69626389 T2	09-10-2003
			DK 824535 T3	02-06-2003
			WO 9635692 A1	14-11-1996
			EP 1221446 A1	10-07-2002
			EP 0824535 A1	25-02-1998
			HU 9801387 A2	28-01-1999
			JP 11506429 T	08-06-1999
			NO 975151 A	10-11-1997
			NZ 308518 A	28-01-2000
			PL 323233 A1	16-03-1998
			PT 824535 T	31-07-2003
			RU 2183212 C2	10-06-2002
			SI 824535 T1	31-08-2003
			SK 150397 A3	04-03-1998
			TR 9701334 T1	21-04-1998
			TW 452579 B	01-09-2001
			US 2003191105 A1	09-10-2003
			US 6531465 B1	11-03-2003
			ZA 9603758 D	10-11-1997
			AT 99295 A	15-01-1997
			AT 69896 A	15-05-1997
			AT 73396 A	15-05-1997
GB 1460377	A	06-01-1977	JP 50093989 A	26-07-1975
			CH 608809 A5	31-01-1979
			DE 2450618 A1	30-04-1975
			FR 2248845 A1	23-05-1975

PATENT COOPERATION TREATY

PCT

REC'D 27 APR 2004

WIPO

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

(Rationalised Report according to the Notice of the President of the EPO published in the OJ11/2001)


Applicant's or agent's file reference IB/G -32500A/1/2/	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/EP03/07603	International filing date (day/month/year) 14/07/2003	Priority date (day/month/year) 15/07/2002
International Patent Classification (IPC) or national classification and IPC C07D501/00		
Applicant SANDOZ GMBH et al.		


1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 2 sheets, including this cover sheet.
- ☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consists of a total of _____ sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 18/12/2003	Date of completion of this report 21/04/2004
Name and mailing address of the IPEA/  European Patent Office D-80298 Munich Tel. (+49-89) 2399-0, Tx: 523656 epmu d Fax: (+49-89) 2399-4465	Authorized officer TZSCHOPPE D A Tel. (+49-89) 2399 2828



I. Basis of the report

The basis of this international preliminary examination is the application as originally filed.

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The question of whether the claimed invention appears to be novel, to involve an inventive step, or to be industrially applicable has not been the subject of the international preliminary examination in respect of the claims which have not been searched (Article 17(2)(a) or (3) and Rule 66.1(e) PCT); see also international search report).

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability

To the extent that the international preliminary examination has been carried out (see item III above), the following is pointed out:

In light of the documents cited in the international search report, it is considered that the invention as defined in at least some of the claims, which have been the subject of an international search report, does not appear to meet the criteria mentioned in Article 33(1) PCT, i.e. does not appear to be novel and/or to involve an inventive step (see international search report, in particular the documents cited X and/or Y and corresponding claim references).